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Abstract
The compound 2-methyl-3-phenyl-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide
(NSC 108406) was identified as an HIV-1 reverse transcriptase inhibitor by the National
Cancer Institute. Using this lead, the Baker group has developed a series of analogues
with various groups at the 3-position that show a spectrum of biological activities. In the
end, the substituents used could not compare to the biological activity of the inhibitor
efavirenz (Sustiva® [trademark]), and so it was decided to synthesize sultams with
alkylethynyl substituents at the 3-position of the sultams in an attempt to mimic the
activity of efavirenz.
Previous research analyzed the proposed novel sultams in the modeling program
FlexiDock contained in the SYBYL package. The FlexiDock modeling performed by
Riyam Kafri gave evidence for unique binding of the proposed sultams in both wild type
and Y181C reverse transcriptase. Another in silico method applied to the novel sultams
was the CoMFA analysis, which looks at the similarities between common compounds
with known biological activities and uses this information to calculate predicted activities
for untested compounds.
Synthesis of the novel ethynyl sultams is achieved by reacting the desired
lithiated alkylethynyl reagent with 3-chloro-1,2-benzoisothiazole 1,1-dioxide, pseudosaccharin chloride. Methods were designed to yield either the mono-alkylated or the bisalkylated products. Various methods for reducing the mono-substituted compounds
were applied to attempt to achieve the desired S enantiomer. Other methods resulted in
the production of a racemic mixture of the reduced compounds. The reduced mono-
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sultams or the bisalkylated sultams are then methylated to yield the desired final
product.
An aryl sultam was also synthesized in a similar method employed by Baker and
co-workers by reacting saccharin with two equivalents of a Grignard reagent of 3bromostyrene. The compound was reduced with the catalyst (R)-Cp*RhCl[(1S,2S)-pTsNCH(C6H5)CH(C6H5)NH2]

[(R)-pentalmethylcyclopentadienylrhodium

chloride-

(1S,2S)-p-toluenesulfonyl-1,2-diphenylethylenediamine] and alkylated with base and
iodomethane. The vinyl group was reacted in a modified SimmonsSmith fashion to
produce a cyclopropyl group in the meta position on the phenyl ring.
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I.

Introduction

A. AIDS and HIV—The Beginning
The human immunodeficiency virus, or HIV, is a virus that is an ongoing menace
to mankind, with several million people either being HIV positive or living with AIDS
(acquired immunodeficiency syndrome), the full-blown disease that it produces. Since
HIV was first reported in 1981, it has become a pandemic, and approximately 34 million
people in the world were living while infected with HIV, while there were 1,700,000
deaths from AIDS in 2011 alone.1 Of the 34 million plus living with HIV in the world in
2012, approximately 9.7 million people were receiving antiretroviral therapy in the loweror middle-income countries.1
When the world became knowledgeable of HIV and AIDS, people believed it
targeted specific groups of people. Since then, it has been determined that HIV is a
virus with no discrimination and the ability to infect anyone. HIV is predominately
transmitted through sexual acts, but can also be transmitted through other methods
such as contaminated blood transfusions and the sharing of used narcotic needles.1
HIV may not have been discovered as the causative agent of AIDS as early as it
was if not for the work by Robert Gallo and co-workers in the 1970s at the National
Cancer Institute, NCI, with the Human T-Cell Leukemia Virus Type 1 (HTLV-1) and its
discovery as a retrovirus that affects humans.2, 3
In June of 1981, the Center for Disease Control (CDC) reported in the Morbidity
and Mortality Weekly Report of cases of five men with a rare Pneumocystis pneumonia.
The pneumonia was reported to the CDC by Dr. Michael Gottlieb and colleagues who
had noticed the infection in several homosexual men.4 What made the pneumonia so
1

unique was that the patients had a lack of CD4 T-cells, helper T-cells, preventing the
body from fighting the infection. It was found that by the time the CDC released the
report, already 250,000 Americans were infected with the disease, which came to be
known as AIDS.4 With the first discoveries in the United States (U.S.) being reported on
homosexual men, the disease began to be known as “the gay disease” and having ties
with the homosexual lifestyle. However, in New York in the same year, Dr. Gerald
Friedland and Dr. Arye Rubenstein began seeing the disease in non-gay men in
injection drug users, and in some cases symptoms in their children.4 After reading the
article by the CDC, two European doctors reported seeing similar cases in their
patients: primarily heterosexual, with the most notable cases including heterosexual
women in Belgium originally from central Africa.4
Further support arose against the idea of AIDS being a homosexual disease
when Dr. Margaret Fischl reported cases to the CDC in 1982 of non-homosexual male
and female Haitians having both Pneumocystis pneumonia and Kaposi’s sarcoma.
However, Dr. Fischl reports the CDC initially did not believe her findings.4
The first signs of AIDS being a viral related situation arose when three
heterosexual men with hemophilia developed symptoms of Pneumocystis pneumonia.
The significance of this comes from the treatment of hemophiliacs with plasma from
donors that is processed through a filtration system that only a virus is small enough to
slip through.4 Another case was found in a 20-month-old infant who had received
several blood transfusions that developed immunosuppressant symptoms. It was
discovered that one out of the nineteen donors of blood for the child had already passed
away from AIDS.4
2

With more and more cases giving evidence to AIDS being caused by a virus,
researchers began an investigation to find the cause of the newly discovered disease.
Gallo began to claim that the source of AIDS could be a retrovirus like HTLV-1. His
initial tests showed patients diagnosed with AIDS as having positive test results for a
retrovirus. It was found later that these patients also had HTLV-1, but at the time Gallo’s
team was convinced that they had discovered a new retrovirus responsible for the
disease, AIDS, and worked to find out more about the retrovirus.5 Gallo goes on to state
in a review from 2004 that it was difficult declaring HIV as the causative agent of AIDS
because AIDS has been known to show signs of infection typically after years since the
actual date of infection, followed by the fact that once AIDS was shown to be present, a
patient already had numerous other infections that could have been confused as the
causative agent.3
After Gallo’s group released information regarding a new retrovirus as the
causative agent in AIDS, a group at the Pasteur Institute in Paris led by Luc Montagnier
were prompted to lead studies on the new retrovirus.5 The group obtained the biopsy of
a lymph node of a homosexual patient with multiple lymphadenopathies and symptoms
that had become known to be early signs of AIDS. The initial studies found that a
retrovirus was present in the lymph node biopsy with ionic requirements of a viral
reverse transcriptase related to that of HTLV, but it had viral core proteins not
immunologically related to the p24 and p19 proteins of sub-group 1 of HTLV.6 Further
studies included comparing the proteins of the newly discovered retrovirus with proteins
of other HTLV species isolated from various cases, which resulted in seeing a relation
between various HTLV species and the new retrovirus, but with some very clear
3

differences. With personal communication with Gallo, Montagnier reported that studies
show the nucleic acid sequences of the new virus have less than 10% homology with
that of other HTLV isolates.6 Even with this new information, Montagnier’s group did not
link the new retrovirus to AIDS at the time because the patient was not diagnosed with
“frank” AIDS.5
Montagnier’s group later went on to collect several isolates of a retrovirus from
AIDS-positive patients and labeled them as IDAV-1 and -2 for immune deficiency
associated virus. However, before Montagnier published information involving IDAV-1
and -2 in 1984, Gallo’s group isolated viruses that did not display immunological crossreactions with HTLVs, and they began to have two isolates continue to grow through
cell-line cultures.5 Gallo et al. would use the experiments involved in the cell-line
cultures to develop a blood test that was later used to confirm the presence of the newly
discovered virus, termed HTVL-III, in 48 different patients.5, 7, 8 From their collection of
evidence through their studies, Gallo’s group was able to determine that HTVL-1, which
was later termed HIV, was the single cause of the disease, AIDS.
With the development of the first conclusive blood test for HIV from Gallo et al.,
donated blood for transfusions could be tested for infection to prevent the further spread
of the virus. Furthermore, with the development of the continuous cell-line cultures,
testing for anti-HIV drugs could be performed such as with azidothymidine (3’-azido-3’deoxythymidine, AZT), the first moderately successful anti-HIV drug.5, 9
B. Possible Origins of HIV
The primate lentivirus group consists of the two strands of HIV and various
simian immunodeficiency viruses (SIV). Among the primate lentivirus group are five
4

different lineages, with HIV-1 and HIV-2 coming from two different lines.10 Since
documentation of the two serotypes of HIV, it has been found that HIV-1 can be
accounted for a majority of infections around the world.11 Viral cluster experiments show
that HIV-1 clusters with that of SIVCPZ, chimpanzee SIV, suggesting that the source of
HIV-1 comes from the chimpanzee subspecies Pan troglodyte troglodytes with evidence
pointing to wild species of P. t. troglodytes in southern Cameroon being the likely
original source.10, 12 This leads to theories of the origin of HIV-1 and 2 as being in the
area of West Africa.
One counter theory from Carel Mulder argues that the differences between HIV 1
and 2 sequences from that of SIV are so distinct that the origin could not have occurred
recently.13 Instead, Mulder argues that HIV has been around for much longer and
evolving with primates along the way.
Studies of the origin of HIV-1 have been estimated to date back as far as the
1920s with the use of molecular clocks, and samples obtained in 1960 has corroborated
this time scale through the analysis of the diversified group M strains of HIV-1.14 It was
also found in the study that a common ancestor of HIV-1, HIV-2, and SIVAGM existed
about 150 years ago instead of the millions of years mentioned by Mulder. 10 The use of
the molecular clock study investigates the viral sequences and notes the different
mutations through time, allowing a rate of change to be estimated. However, there is the
idea of host-dependent evolution and the molecular clock model does not take this into
account.10

5

C. The Lifecycle of HIV
1. Overview
There are several methods of treatment for HIV as of now with up to 20 different
clinical pharmaceuticals on the market, but to understand how these methods of
treatment work, HIV’s life cycle of infection to reproduction should be discussed. The
infection begins with the virus attaching to and becoming a parasite on a target cell
(Figure 1). The virus binds via its glycoprotein-120 (gp120) to the CD4 receptors on Tlymphocytes, macrophages, monocytes, and/or dendritic cells. From here, the gp120
that bonded to the CD4 receptors binds to one of the chemokine receptors, CXCR4 or
CRC5, which leads to the insertion and uncoating of the virus and insertion of its RNA
and key enzymes for reverse transcription and nucleic acid integration.5 Once inside
the cell, the viral RNA goes through reverse transcription with the HIV enzyme, reverse
transcriptase, to generate a complimentary DNA strand of the viral RNA.

Next a

double-stranded HIVDNA is then produced and then proceeds to integrate into the
cellular genome through the enzyme HIV integrase. The infected cell then becomes
activated, resulting in the production of messenger RNA encoding for viral proteins, and
then, within approximately 2.5 days of infection, virus particles begin budding out of the
cell. Once out of the cell, viral polyproteins are cleaved by HIV protease, which results
in the release of individual viral particles to infect other cells.5

6

Figure 1. The HIV life cycle, from fusion to budding.15

7

2. Viral Entry—Fusion
For the virus to infect a host cell, it must first gain entry into the cell, and this
begins with a process known as attachment followed by fusion. The virus first begins by
the cleavage of glycoprotein 160 (gp160) into glycoprotein 120 (gp120) and gp41.16
This step is followed by the binding of the subunit (gp120) of the viral envelope to the
CD4 receptor site on the host cell (T-lymphocyte) wall.17 Once the gp120CD4
interaction has occurred, the virus proceeds next to binding to either a CCR5 (HIV
strains that infect macrophages, M-tropic or R5 strains) or CXCR4 (strains that infect Tcells, T-tropic or X4 strains) chemokine co-receptor.18 Following the gp120 and
coreceptor binding, the gp41 subunit is altered to prepare itself for the formation of the
pre-fusion intermediate designated the extended coiled-coil.17 Before the coiled-coil
inserts into the target cell membrane, a six-helix bundle, nicknamed the hairpin
conformation, forms from what is known as the C- and the N-terminal heptad repeats of
gp41 coming into a tight association together as the fusion peptide and the
transmembrane domain of gp41 come into apposition bringing the two membranes, viral
and target, close to each other allowing the merger to proceed.17 This six-helix bundle
forms a fusion pore that allows the release of the viral capsid into the cytosol of the
target cell.17
3. Reverse Transcription
The reverse transcriptase enzymes of retroviruses perform up to three enzymatic
activities. These enzymatic activities include: an RNA-dependent DNA polymerase
(RDDP), ribonuclease H (RNase H), and a DNA-dependent DNA polymerase (DDDP).
The enzymes execute the steps in the order of copying a plus-strand RNA genome to
8

produce a minus strand of DNA (RDDP), removal of the plus-strand RNA template
(RNase H), and the synthesis of a plus-strand of DNA with the minus-strand of DNA
acting as a template (DDDP).19
The RT of HIV is a heterodimer consisting of a large p66 subunit (66-kDa) 560
amino acids in length and a small p51 subunit (51-kDa) 440 amino acids in length with
common N termini.19, 20 Both p66 and p51 contain the polymerase domain of RT (RDDP
and DDDP), while a C-terminal fragment that is removed from the p66 subunit is
involved with the RNase H domain of RT.19 In the activity of the two subunits, it has
been found as homodimers, they remain active, but as a monomer, both subunits
become inactive.21 Furthermore, altering the p51 subunit by mutation shows little effect
on the activity, while mutating the p66 subunit in some way causes the heterodimer to
be inactive.22
The structure of HIV-1 RT, as seen in an X-ray crystal structure, shows that
overall the enzyme is asymmetric, but both p66 and p51 contain subdomains labeled as
“finger,” “palm,” “thumb,” and “connection.” The p66 subunit is positioned such that the
finger, palm, and thumb domains are open in a sense of forming a cleft, termed a “hand”
shown to be the active site of the enzyme (Figure 2). The p51 subunit and the p66 are
joined at the connection domain, which is rotated such as that the palm of p51 is hidden
within the enzyme.19 This shape supports the activity discussed previously of it
appearing the p66 subunit being largely responsible for reverse transcription to proceed.
Both the polymerase and the RNAse H of RT reside in the p66 subunit. The two
active sites are located as such that a (+)-strand RNA template (tRNALys) enters
“through” the fingers and thumb of RT where it attaches to the 18 nucleotide primer
9

binding site (PBS).23-25 The RNA strand passes through the RDDP enzyme to be
transcribed into a (-)-strand of DNA starting from the 5’ end of the (+)-strand RNA. From
here the combined RNA/DNA strand is fed into RNAse H, which removes the RNA
strand so that the (-)-DNA strand could be used as a template to form a complete
double stranded helix of viral DNA as it is passed through the DDDP. It has been
theorized that the RDDP and the DDDP are one in the same.19 After the DNA replication
process has completed, the integration process begins.
Since its discovery, there have been crystal structures analyzed and
characterized of RT as it is bound with an inhibitor, a double-stranded DNA, and a
polypurine RNA:DNA double strand and unbounded RT. Through each structure, it was
seen the flexibility of the thumb and fingers of the RT active site. 26-28 The shape of the
RT enzyme is altered at the thumb position when RT is either bound or unbound. When
RT is unbound, the thumb is placed in an upright position, residing in close proximity of
the finger subdomains.29 It was found that there are two small and weak interactions
between the thumb and fingers at the Arg78 amino acid of the fingers with the main
chain of the thumb and a nonpolar interaction between Phe61 in the fingers and Leu289
of the thumb. These interactions allow for the mobility of the thumb to be flexible and
free because of their weak interactions. The shape of the active site with the presence
of either a double-stranded DNA or the RNA:DNA double strand showed a similar
shape with the finger and palm subdomains interacting heavily with the substrates
present in the cavity.27, 28
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The ability for the catalytic site to be so flexible has allowed for RT to be a viable
target for inhibition (Figure 2). (The mechanism for NNRTIs shall be discussed in detail
in the section on non-nucleoside reverse transcriptase inhibitors below.)

Figure 2. Reverse transcriptase with efavirenz (green) in binding pocket
of palm. (pdb code 1ikw).
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4. Integration
Integration is an important step in the viral replication cycle, in that it is
responsible for ensuring a stable relationship between the viral DNA from reverse
transcription and that of the hostcell chromosome.19 Before integration begins, a preintegration complex forms, which isolates show the complex involving the linear viral
DNA, reverse transcriptase, nucleocapsid integrase, and two cellular proteins (highmobility-group, HMB-I(Y), and barrier-to-autointegration factor, BAF). Once formed, the
pre-integration complex of HIV-1 enters the nucleus through the nuclear pore, where it
then catalyzes integration.30
Integrase is responsible for cleaving the 3’-end groups of the viral DNA to expose
hydroxyl groups at the 3’-ends so that host DNA can connect to the viral DNA. Once
connected, the exposed viral DNA is inserted into the cellular DNA of the host, and this
action can occur at any location on the host cellular DNA.31
After integration is complete, a viral polyprotein is synthesized by use of cellular
machinery within the host cell.32 Once synthesized, the viral polyprotein is subject to
cleavage by the enzyme HIV protease.
5. Protease Interaction
As previously stated, the next step in the replication process is cleaving of the
polyproteins in the protease (PR) enzyme to form mature viral particles. The HIV PR is
composed of 99 amino acids, and belongs to the aspartyl protease class. All retroviral
PRs, especially those of HIV, are monomers that contain a single conserved active-site
triplet, Asp-Thr/Ser-Gly, and upon activation the PRs become a dimer.19 As stated, the
protease is responsible for cleaving the polyproteins, but so far no distinctive primary
12

sequence of amino acids has been found within a substrate polyprotein at the cleavage
sites. Some common characteristics to be found are that the area around the cleavage
sites are hydrophobic sequences, and a strongly conserved feature is at the N-terminal
side of the cleaved bond.33 The protease of HIV is an attractive target for inhibition,
because each kind of retrovirus has to rely on its own PR for maturation to occur. 34
D. Methods of Treatment: Chemotherapy
These processes necessary for the reproduction of HIV provide several points of
pharmaceutical intervention, and several treatments have been developed involving
inhibitors for the different processes. However, HIV has a high rate of mutation through
its replication, with reverse transcriptase having the highest affinity for error. With this
being the case, when a patient is treated with anti-virals that are active against wild-type
HIV, the mutant strains that develop with a resistance to the inhibitor proceed on to
replicate further making treatment difficult. Nevertheless, given the fact that an anti-HIV
vaccine has eluded researchers for more than 30 years, and even today there seems to
be little hope for an effective vaccine,35, 36 chemotherapy is in reality the only method for
combating the virus.
As previously discussed, the method of HIV reproduction is the act of the virus
attaching to the cell at the CD4 receptor, binding to a co-receptor, fusion of the cell
membrane, reverse transcription, integration, and the synthesis of new viral particles
from the cleavage of polyproteins by protease. Each step in the replication process has
been studied with the intent of designing inhibitors for treatment in anti-HIV therapy, with
some inhibitors already on the market for patient use.
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1. Virus Attachment and Fusion Inhibitors
i.

CD4 Receptor Inhibitors

As already discussed, the initial action of viral replication is the attachment to the
CD4 receptor on the host cell wall. There are currently no pharmaceutically compounds
approved on the market for inhibiting cellular CD4 receptors; however, there are classes
of compounds showing inhibitory activity in studies. A series of analogues of
cyclotriazadisulfoamide (Figure 3) are being investigated for preventing the viral
attachment to the CD4 receptor.37, 38 The inhibitors do so by down-modulating the CD4
receptor expression on cell surfaces without affecting other receptors, CXCR4 and
CCR5.39,

40

CADA has been found to be able to work alongside with other anti-HIV

inhibitors such as NNRTIs, NRTIS, and protease inhibitors, which allows it to be added
to the current method of HIV treatment by a cocktail of inhibitors.41

14

ii.

gp120 and gp41 Inhibition
A series of inhibitors has been identified for activity in preventing the gp120 from

attaching to the CD4 receptor. It has been assumed that whether the inhibitor is
naturally occurring or synthesized it acts by shielding off the positively charged sites in
the V3 loop of the viral envelope of gp120, therefore preventing viral attachment. 18
Among these is a group of plant lectins from Galanthus nivalis (GNA) and Hippeastrum
hybrid (HHA) that are mannose specific. The lectins have low toxicity and are
considered to act as topical microbicides.42 One microbicide being investigated is the
protein cyanovirin-N isolated from the cyanobacterium Nostoc ellipsosporum.43 Another
potential highly active lectin isolated from red algae, Griffithsia, being studied is
griffinsin.44, 45 Both cyanovirin-N and griffithsin bind to the gp120 and inhibit the binding
to the CD4 receptor both dependently and independently. Another potential gp120
inhibitor for viral attachment to CD4 is BMS-378806 [(4-benzoyl-1-[4-methoxy-1Hpyrrol[2,3-b]pyridine-3-yl]oxyacetyl)-2-(R)-methylpiperazine]. Unlike the two lectins,
BMS-378806 has shown to be only active with dependent binding with CD4; this means
it only affects the CD4—gp120 interaction.46, 47 The three gp120 inhibitors discussed are
shown in Figure 4.
Another type of viral attachment inhibitors is that of the gp41 class of inhibitors.
Most notable of these is enfuvirtide, as it has been FDA approved for HIV treatment as
of March 2003. Enfuvirtide (Figure 5) is a linear, 36 amino acid synthetic peptide
resembling part of the HR2 region of gp41 causing it to act as a competitive inhibitor
against HR1 binding.48 A series of smaller molecule peptidic fusion inhibitors (Figure 5)
15

are being investigated and are currently showing better pharmacodynamics than
enfuvirtide.18
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iii.

Co-receptor Inhibitors
As previously discussed, after the viral gp120 has been bound to the CD4

receptor, the virus then attaches to either of two co-receptors, CCR5 or CXCR4. The
class of co-receptor inhibitors has included proteins, small molecules, and antibodies.
The inhibitors interact with either the CCR5 or CXCR4 receptors or the viral envelope in
order to prevent the interaction of the co-receptor with the viral envelope. Among the
inhibitors developed, the first one was TAK 779 as an inhibitor of the CCR5 co-receptor
(Figure 6). Compound SCH351125 has shown activity, but is not yet in clinical trials.
The inhibitor maraviroc was approved by the FDA in August of 2007 and is currently
part of treatment methods for co-receptor inhibition of HIV. Vicriviroc is currently in
Phase III clinical trials.
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Figure 6. Inhibitors affecting CXCR4 and CCR5.

2. Integrase Inhibitors
Inhibitors for integration are relatively new for HIV treatment. The compound
raltegravir (Figure 7) was approved by the FDA in October of 2007. Raltegravir acts by
inhibiting the final step of the integration process, blocking the strand transfer of viral
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DNA to the host cell DNA.18 Another integrase inhibitor is elvitegravir, which was
approved by the FDA as recently as August 2012.49

3. Protease Inhibitors
Unlike the previous groups of inhibitors, protease inhibitors are a larger class of
FDA-approved compounds. The protease inhibitors act as competitive inhibitors against
the protease enzyme in its action to cleave viral polyproteins. The inhibitors are
substrates of CYP3A4, and they either act by inhibiting or inducing specific CYP
isoenzymes at varying degrees.18 The earliest FDA-approved protease inhibitors were
indinavir and saquinavir (Figure 8) approved in December of 1995, and most recently
the protease inhibitor darunavir (Figure 8) was approved in June 2006.
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4. Reverse Transcriptase Inhibitors
The process of reverse transcription has been highly investigated for inhibition
studies of the RT enzyme.9 Reverse transcriptase has been found to have three types
20

of inhibitors: nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse
transcriptase inhibitors (NtRTIs), and non-nucleoside reverse transcriptase inhibitors
(NNRTIs).
NRTIs and NtRTIs are competitive inhibitors that require activation to their
triphosphate forms by the host cell kinase enzymes.18 Once activated, the NRTIs bind to
reverse transcriptase at the active site and cause chain-termination of the viral DNA by
mutating reverse transcriptase.6, 50 These inhibitors are also able to be integrated into
the viral DNA being synthesized in RT causing the chain elongation to be terminated
because of the lack of a 3-OH preventing the formation of phosphodiester linkages.18, 51
The NRTIs have shown toxicity because of the partial inhibition

of human DNA

polymerase, but the level of toxicity is dependent on each NRTI. 18, 51
Figure 9 shows five of the NRTIs and an NtRTI on the market as of 2012. The
first compound in the figure, AZT, was the first anti-HIV drug approved by the FDA for
treatment.52 After the discovery of AZT, various NRTIs were synthesized by either
adjusting the nucleobase, the attached sugar moiety, or both. This method lead to the
design and synthesis of emtricitabine, as one of the more potent NRTIs on the market,
especially in conjecture with the NRTI stavudine, and the NNRTI efavirenz (will be
discussed later).52
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Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are highly specific,
noncompetitive inhibitors and require no activation for them to bind to RT. NNRTIs are
able to be structurally diverse in their make-up, while most share a butterfly wing shape
when bound in the NNIBP.53 NNRTIs have been shown to bind to a site distinct from the
NRTIs on reverse transcriptase known as the non-nucleoside inhibitor binding pocket
(NNIBP) (to be discussed in more detail in section E).5, 50 The NNRTI class have shown
to bind specifically to the RT of HIV-1 and not of HIV-2 or other retroviruses’ RT.54 The
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reason for inactivity with HIV-2 is due to the residues making up the allosteric binding
pocket of HIV-2 compared to HIV-1. The pocket of HIV-1 consists of hydrophobic
aromatic residues, while the wild type HIV-2 pocket has primarily aliphatic residues.55
The NNRTIs have been shown to have effective concentration (EC 50) as inhibitors at
concentrations 50% lower than that of the cytotoxic concentration (CC50).54
The

first

class

of

NNRTIs

to

be

discovered

belong

to

the

TIBO,

tetrahydroimidazo[4,5,1-jkj][1,4]benzodiazepine-2(1H)-one and -thione, group. The
studies involved the screening of around 600 molecules led to the TIBO ring system
with a ketone, R14458, and after alterations to the compound by changing the ketone to
the thione, the allyl group to 3-methyl-2-butenyl, and adding a chloro group to the
aromatic ring produced R82913 with IC50 1.5 nm, a potency 41,000-fold greater than
R14458.56, 57 The TIBO group were then used in the investigation of the mechanism of
inhibition of RT to better understand the act of inhibition for further development of
compounds.58
Although the TIBO group had been the first class to be designated as NNRTIs,
they weren’t the first NNRTIs discovered. The HEPT, 1-[(2-hydroxyethoxy)methyl]-6(phenylsulfanyl)thymine) compounds had first been discovered in 1989 by Baba et al.;
however, they were first described as NRTIs.58, 59 Kinetic studies were performed with
HEPT compounds, and it was eventually found that they did not compete with the
thymidine triphosphate during the polymerization step. Furthermore, the triphosphate of
HEPT was a weaker inhibitor than that of HEPT itself. It was not until the investigation of
the mechanism of inhibition of the TIBO class that it was suggested that HEPT could
also be an NNRTI.56
23

Since the discovery of TIBO and HEPT as NNRTIs, they have been discontinued
in clinical use, but there have since been several generations of new NNRTIs. 60 Among
the first generation of NNRTIs are the compounds nevirapine and efavirenz. Since their
approval by the FDA, HIV-1 has resulted in mutant strains of RT that have shown
resilience to the first generation. The second generation of NNRTIs, for example,
etravirine or rilpivirine, were designed to combat the effect of the Y181C or K103N
mutation with emphasis on interactions with the conserved residues of RT like W229.52
Compounds such as efavirenz inhibit the RT process at concentrations in the
nanomolar range. Structures of the mentioned NNRTIs can be seen in Figure 10.
As mentioned earlier, once bound in the NNIBP, the inhibitors take on a folded
“butterfly” wing-like shape. The later inhibitors such as nevirapine and efavirenz were
designed to abate the formation of this shape.61 To better adapt the butterfly wing
shape, the inhibitors must meet three criteria: two -systems, a body or bridge that
connects the two -systems, typically made up of a thiocarbonyl, a carbonyl, or a
sulfonyl moiety, and a methyl or some other alkyl group at the meta-position of the
extended -system. In the end, the NNRTIs that meet this criteria form a rigid
structure.53
Some NNRTIs do not exhibit the butterfly shape or it isn’t as obvious. In
opaviraline and UC-781, the top wing (the -system that interacts with the residues Tyr
181, Tyr 188, and Trp229) is decreased in size or even nearly absent compared to other
NNRTIs. The compounds delavirdine and TSAO-T do not even seem to resemble the
butterfly shape.54
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E. The Non-Nucleoside Reverse Transcriptase Inhibitor Binding Pocket
The NNIBP (Figure 11), as discussed, is the site for attachment of NNRTIs. It is
an allosteric, hydrophobic site that is roughly 15 Å away from the catalytic site of RT and
is between 620 to 720 Å3 in size.52, 58 The site is located within the palm of the p66
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subunit of RT. The pocket is comprised of amino acid residues 105110 and 179191
of the beta-sheets 4, 7, and 8, residues 224241 of the sheets 9, 10, and 11,
residues preceding the 4, 98104, and the amino acid residues 59, 132, 138, 139,
141, and 318.54,

58

The pocket mouth contains the two residues Pro225 and Pro236

which have been theorized as “closing the door” of the pocket once the NNRTI has
entered.54 Specifically, the roof of the pocket is formed by the aromatic residues Tyr
181, Tyr 188, and Trp 229, and the walls are made up of Leu 100, Val 106, and Leu
234. The floor of the pocket consists of a chain of three lysines: Lys 101, Lys 102, and
Lys 103.54
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Figure 11. The non-nucleoside reverse transcriptase inhibitor binding pocket.

Interestingly, crystal studies of RT without a ligand attached found the absence of
the NNIBP, and it was found only to exist when bound with an inhibitor. 26 The formation
of the pocket results in the induction of a conformational change of the side chains of
Y181 and Y188 in the direction of the catalytic site, resulting in a related movement of
the 4-7-8 sheet and three of the amino acid residues at the catalytic cite by 2 Å.62 It
is theorized the inhibition is caused from this change in the beta-sheets and the catalytic
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triad. The pocket will typically conform to a similar shape independent of the structure of
chemically different NNRTIs.58
The NNRTIs each have their own unique interaction within the binding pocket,
but the differences are quite minor from each other. The most important interaction for
the NNRTIs to exhibit is the  interaction felt with one or more of the residues Tyr
181, Tyr 188, Trp 229, and/or Tyr 318, with the more interactions occurring the better.
Another interaction is the electrostatic charges occurring with residues Lys 101, Lys
103, and Glu 138 with the aromatic wing of an NNRTI. A third interaction to occur with
ligands and the pocket is the van der Waals interaction that occurs with resiudes Leu
100, Val 106, Val 179, Tyr 181, Gly 190, Trp 229, Leu 234, and Tyr 318. A potential final
interaction are hydrogen bonds that occur with the ligand to the main chain peptide
bonds of Lys 101 and/or Lys 103.54
F. Mutations Induced by NNRTIs
Since the use of NNRTIs began, several mutations arose leading to drug
resistance of NNRTIs. These mutations differ from those formed from NRTI treatment;
furthermore, NNRTI induced mutant strains retain sensitivity to NRTI treatment and vice
versa.63 Unlike NRTI-induced mutations that can occur throughout RT, NNRTI induced
mutations occur only in the NNIBP.63 Most mutations are as simple as one amino acid
being changed to another with variability on whether one inhibitor is made inactive or
not. The first two resistant mutations seen were the K103N (Lys 103  Asn 103) and
the Y181C (Tyr 181 Cys181) strains, both of which rendered almost all known
NNRTIs inactive. In some extreme cases, double mutations have occurred. The more
prevalent double mutations are K103N/Y181C, L100I/K103N, and K101D/K103N. 64
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Table 1 shows a list of possible mutations and the NNRTI that was used in the
treatment that led to the mutation.
A valid question arises, “Since NNRTIs give rise to rapid mutation, are these
viable inhibitors to develop.” Two schools of thought offer discordant opinions. One is,
yes, mutations seriously impede these drugs and they should be abandoned. The other
is, no, we need a succession of ever-more potent NNRTIs to meet the challenge of
mutant strains. Moreover, NNRTIs seem most effective as components of 3- or 4-way
cocktail regiments for long-term therapy.65

Table 1. Mutations with resistance to NNRTIs and the NNRTI used in treatment.
nevirapine (NEV), deliviradine (DLV), and efavirenz (EFV).54

Amino Acid
Mutations in RT
98-Ala-->Glu
100-Leu-->Ile
101-Lys-->Glu
103-Lys-->Asn/Thr
106-Val-->Ala
108-Val-->Ile
135-Ile->Met/Thr/Leu
179-Val-->Asp/Glu
181-Tyr-->Cys/Ile
188-Tyr->Cys/His/leu
190-Gly->Glu/Ala/Ser
225-Pro-->His
233-Glu-->Val
236-Pro-->Leu
238-Lys-->Thr

NNRTI used to cause
mutation
NEV
NEV, DLV, EFV
EFV
NEV, DLV, EFV
NEV,DLV
NEV,DLV
EFV
EFV
NEV, DLV, EFV
NEV, DLV, EFV
NEV, DLV, EFV
EFV
DLV
DLV
DLV
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G. Sultams: A novel class of NNRTIs
1. The Discovery of Sultams as NNRTIs
The initial design of the sultam class of NNRTIs resulted from Gussio et al.
developing a structure for the NNIBP with an all-atom model from a crystal structure of
reverse transcriptase complexed with the inhibitor nevirapine.66 The group used the
known C- coordinates from the crystal structure with only a resolution of 2.9 Å. After a
series of tests using structural probes based on nevirapine and nevirapine analogs with
known structureactivity relationships, a reasonably accurate and complete NNIBP was
developed. From here, new NNRTIs could be analyzed in this more complete binding
pocket model.66
After

comparisons

of

nevirapine

analogs,

a

3-D

QSAR

(quantitative

structureactivity relationship) model was developed. Using the 3-D QSAR and density
functional theory (DFT), a stereoelectronic pharmacophore was designed to use in
designing new inhibitors.66 With this newly designed pharmacophore, Gussio and coworkers at the National Cancer Institute (NCI) conducted a search of its database of
over 200,000 compounds. After several runs through the database with parameters
designed to narrow the field each run, a list of 33 potentially active molecules with 26 of
these being structurally novel molecules. Among the 33 molecules were the compounds
nevirapine and NSC-119833 (Figure 12).66
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Another search through the NCI database produced a few new results of active
compounds. One compound to come out of this was NSC-108406 (Figure 13). NSC108406 showed inhibition activity with an IC50 of 0.5  0.3 M and an EC50 of 1.5  1.0
M.67 NSC-108406 belongs to a family of compounds known as sultams, which the first
synthesis of a similar compound was discussed by Hauser and co-workers, and other
methods were developed by Baker and co-workers, unpublished work, to produce over
65 analogues of NSC-108406.68-72
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2. The Synthesis of Sultams
The sultams discussed here are derivatives of isothiazoles with an aromatic ring
being fused at the C4 and C5 positions with numbering starting with 1 at the sulfur
atom. The Baker lab developed sultams resembling that of the compound shown in
Figure 10 with the aromatic ring attached to the isothiazole ring being ring A, Ring B the
heterocycle, and Ring C another aromatic ring. The initial studies had the nitrogen atom
being either secondary or tertiary depending on whether R 1 was a hydrogen or an alkyl
group, and with various substituents at either C6 or C7 in ring A. It was later discovered
that altering groups at C6 or C7 decreased activity, and it was the effect of using various
substituents at the meta position of Ring C, labeled R2, that enhanced activity. The
original method by the Baker group to synthesize the sultams is shown in Scheme 1.
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In Scheme 1, the first step is the coupling of a primary amine with a substituted
benzenesulfonyl chloride to form compound 1-1. When 1-1 is reacted with nbutyllithium, the hydrogen at the ortho position is lithiated, which reacts with a metasubstituted benzaldehyde (1-2) to produce 1-3. Upon reaction of 1-3 with a protic acid,
the racemic final compound 1-4 is formed from the cyclization of 1-3. Initial methods
used a chiral semi-preparative column on HPLC to separate the enantiomers, where
they were sent to NCI for biological testing.68, 70
The original method for synthesizing the sultams was flawed when analogues
with a halogen as a substituent was desired because of the tendency of alkyllithium to
perform a lithiumhalogen exchange reaction. To circumvent the production of side
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products, a new method was developed, Scheme 2. A halogen-substituted orthoaminobenzophenone (2-1) was first reacted with HONO to produce a diazonium
compound, which upon reaction with SO2 in ionic copper produced 2-2. Ammonia was
used to perform a condensation on 2-2 to produce 2-3, which was then hydrogenated to
form racemic 2-4. The final step involved the alkylation of the nitrogen to produce
racemic 2-5.69, 73

In the early days of the project other methods were designed, patented, and
employed in the laboratory as shown in Scheme 3. Compound 3-1, 2,4(dimethoxyphenyl)-(4-methoxyphenyl)methylamine was reacted with benzenesulfonyl
chloride in the presence of a base to form 3-2. After ortho-lithiation of the aromatic ring
attached to the sulfur, benzaldehyde or substituted benzaldehyde was added to yield a
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mixture of 3-3 and 3-4. Sulfuric acid was then used to cyclize the ring to produce the
sultam 3-5.69

A fourth method was developed to involve a CF3 group at the C3 position in ring
B, Scheme 4. The method starts with reacting tert-butylamine with benzenesulfonyl
chloride to yield 4-1. The nitrogen atom in 4-1 is deprotonated with sodium hydride,
which the negative charge performs an SN2 reaction on iodomethane to form 4-2.
Compound 4-2 is ortho-lithiated with n-BuLi and then reacted with 2,2,2-trifluoro-1phenylethanone to produce 4-3, which is cyclized with sulfuric acid to produce the
racemic compound 4-4.69
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As it was done with the final compound in Scheme 1, the final compounds in
Schemes 23 (2-5, 3-5, and 4-4) were purified into the desired enantiomer
predominately with chiral separation with a Chiralcel OD column on HPLC. Some
enantiomers were purified with derivitization into the respected diastereomer and then
separated with liquid chromatography and recrystallization.
Initial biological studies showed a decrease in activity of compounds with altered
substitution on Ring A as directed by models supplied by the NCI team. When these
diminished activities were realized, the Baker group re-evaluated the model and
determined that Ring C was the more likely candidate for insertion into the NNIBP of the
enzyme; hence, modifications were made on this part of the molecule. Since Ring A
was to only be unsubstituted, the Baker group developed a method of synthesizing
analogues with various substituents on Ring C starting initially from saccharin. Using
methods developed by Abramovitch and co-workers, saccharin was reacted with 2
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equivalents of an aryl magnesium bromide or chloride to yield 5-1.74 Initially, 5-1 was
reduced with a ruthenium chiral catalyst developed by Noyori et al. to yield the desired
enantiomer 5-2.75, 76 The nitrogen atom was deprotonated with Cs2CO3 and alkylated
with a methyl group from iodomethane giving the final enantiopure compound 5-3.

As shown in Scheme 5, a chiral TsDPEN-Cp*rhodium chloride catalyst was also
used in the asymmetric reduction of 5-1 to 5-2. The idea of the use of rhodium came
from an article in C & E News about the use of rhodium being used to reduce imines to
amines effectively.77 The Baker group set forth on the synthesis of a chiral rhodium
catalyst with related ligands to the Noyori catalyst previously used. The rhodium catalyst
was prepared by reacting pentamethylcyclopentadienylrhodium chloride dimer with
either (1R,2R)-N-p-toluenesulfonyl)-1,2-diphenylethylenediamine [(1R,2R)-TsDPEN] or
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[(1S,2S)-TsDPEN] to form the red R,R-catalyst or the S,S-catalyst, respectively.78 As
one can see in Figure 14, the catalyst has three chiral centers: the two carbons in the
TsDPEN ligand and the rhodium metal; however, the catalyst will be referred to as
either R,R or S,S. The catalyst was characterized by single-crystal X-ray diffraction
analysis of the R,R isomer of the catalyst.78 Experiments were performed with a 5:2
formic acidtriethylamine azeotrope as the hydrogen source to test the viability of the
catalyst on various imines, differing solvents, time, and different substrate-to-catalyst
ratios. It was found the catalyst resulted in better enantioselectivity in polar solvents,
and the preferred solvent of choice was dry dichloromethane. In some cases, the
catalyst performed the reduction in as little as 10 minutes at room temperature, but it
was safe to run the reaction up to say 30 minutes. The catalyst performed well with a
S:C ratio of 200:1 compared to the Noyori catalyst with Ru of 100:1. It was found that in
most cases it could be said that the R,R catalyst resulted in the S enantiomer of the
product, and vice versa, but this result was dependent on the substitution on the imine
substrate. In a case of 3-phenyl-1,2-benzisothiazole 1,1-dioxde, the resulting product
was the S enantiomer with the use of the R,R catalyst, while 3-(2-chlorophenyl)-1,2benzisothiazole 1,1-dioxide with the same catalyst would result in the R enantiomer
illustrating a play on CahnIngoldPrelog priorities.78
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The catalyst was found to be quite stable at room temperature, and it even was
found to be effective at cold or warm temperatures with little effect on the
enantioselectivity.
With the new method involving saccharin as the starting material, and the highly
effective rhodium catalyst, the possibility of synthesizing more and new sultams with
defined stereochemistry could be investigated for potential anti-HIV activity.
3. The First Sultams with Enhanced Activities
As previously mentioned, it was found that the most active compounds involved
substituents on the meta position of the C ring. Among the substituents synthesized and
tested, four stood out as having the highest inhibition activity (Figure 15). All four
compounds were synthesized as is shown in Scheme 5. The activities of the
compounds can be viewed in Table 5, but the most active of the four is the compound
(S)-3-(3-methylphenyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1-dioxde

with

an

EC50 of 0.037 M (work unpublished).72 However, the compound Efavirenz from
Sustiva® showed higher activity, and the Baker group sought out a way to make a
comparable compound to efavirenz with similar if not better activity (work
unpublished).72
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H. FlexiDock Modeling
To begin the process to look for similiarly active sultams to efavirenz, Dr. Kafri
used the FlexiDock modeling tool of the program SYBYL as an investigative resource
for potentially interesting binding in the NNIBP of HIV RT with new compounds.79 Kafri
prepared each novel compound designed for the project in the SYBYL modeling
program (Figure 16). Each compound was drawn and minimized with the Tripos Force
Field and GasteigerHückel charges. Each compound was docked into the NNIBP of
the modeled RT crystal structure with the inhibitor efavirenz by superimposing the
sultam on top of efavirenz. After preparing the FlexiDock file to process the sultam’s
effect in the pocket, the potential hydrogen bonds, the hydrogen bond angles, and
distances of the hydrogen bonds in the pocket to the sultam were observed. In Kafri’s
findings, the sultams showed unique binding in the pocket that had some similarities
and some differences compared to efavirenz’s binding in the pocket.79
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Table 2 shows the comparison of efavirenz to the mono-alkylated sultams:
cyclopropylethynyl, cyclobutylethynyl and tert-butylethynyl, within the NNIBP as studied
by Kafri. In binding studies, it is generally expected that a strong hydrophobic interaction
should show a distance between residue and ligand being less than 4 Å, a moderate
interaction being 45 Å, and anything larger than 5 Å is considered a weak interaction. 80
With this knowledge, the three mono-alkylated sultams have some form of interaction
within the binding pocket with the interaction with Tyr 183 being the weakest at roughly
7.5 Å with all four inhibitors. The cyclopropyl sultam shows the closest similarity with
efavirenz interaction with Lys 101 at 2.10 Å compared to efavirenz 2.06 Å, but both the
cyclobutyl- and tert-butylethynyl sultams still showed at least a moderate or strong
interaction respectively to Lys 101. The substituents at the end of each ethynyl group:
cyclopropyl, cyclobutyl, and tert-butyl, all shared similar distances from Tyr 188 and Trp
229 with almost stronger interactions occurring throughout the sultam group.
Interestingly, only the cyclopropyl sultam showed a hydrogen bond present at an angle
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wt RT
Residue in
wt RT
Lys 101
Tyr 181
Tyr 183
Tyr 188
Trp 229
Tyr 318

C=O
CP

Ar

Table 2. Distance of NNIBP residues to ligands and angles of
hydrogen bonds if present with wt RT (wt RT). (CP =
cyclopropyl; Ar = aromatic ring; CB = cyclobutyl; t-Bu = tertbutyl.79
Cyclopropylethynyl
Efavirenz
Sultam
Cyclobutylethynyl Sultam
Distance
Angle of
Distance
Distance
(Å)
H-bond
(Å)
Angle
(Å)
Angle
2.06
98.55°
SO2
2.10
115°
SO2
4.27
-2.54
CP
4.20
CB
4.61
7.23
7.85
7.54
5.96
5.60
4.6
4.49
4.54
4.01
5.84
Ar
6.11
Ar
5.95
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tert-Butylethynyl Sultam
Distance
(Å)
Angle
SO2
3.00
-t-Bu
5.09
7.88
4.30
4.55
Ar
4.91

Residue in
Y181C
Lys 101
Cys 181
Tyr 183
Tyr 188
Trp 229
Tyr 318

C=O
CP

Ar

Table 3. Distance of NNIBP residues to ligands and angles of
hydrogen bonds if present with mutant RT Y181C (Y181C).
(CP = cyclopropyl; Ar = aromatic ring; CB = cyclobutyl; t-Bu =
tert-butyl.79
Cyclopropylethynyl
Cyclobutylethynyl
tert-Butylethynyl
Efavirenz
Sultam
Sultam
Sultam
Distance Angle of HDistance
Distance
Distance
(Å)
bond
(Å)
Angle
(Å)
Angle
(Å)
Angle
2.31
97.76°
SO2
2.19
119.06° SO2
2.31
124° SO2
2.13
127°
-CP
-CB
-t-Bu
-7.26
7.86
7.7
7.19
3.99
4.32
4.41
4.19
4.04
5.24
4.87
4.75
5.00
Ar
4.86
Ar
4.85
Ar
4.74
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of 115 compared to efavirenz at 98.55. An example of a sultam binding in the NNIBP
can be seen in Figure 17.

Lys 101

Tyr 181

Tyr 188
Trp 229

Figure 17. Efavirenz (green) and cyclopropylethynyl sultam (red) in the NNIBP of
wt RT.
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Lys 101

Trp 229

Tyr 188
Tyr 181

Figure 18. Efavirenz (green) with 3-methylphenyl sultam (red) in NNIBP of
wt RT.

Figure 18 shows the sultam (S)-3-(3-methylphenyl)-2,3-dihydro-2-methyl-1,2benzisothiazole 1,1-dioxide in the NNIBP of wt RT with efavirenz. Compared to
efavirenz, it is located in a different configuration in the binding pocket while still
conforming to the traditional butterfly wing shape. The 3-methylphenyl sultam is the
most biologically active sultam synthesized to date with an EC50 of 0.037 M, while
efavirenz has activity in the nanomolar range. However, if the 3-methylphenyl sultam is
compared to the cyclopropylethynyl derivative sultam in Figure 17 and efavirenz, the
cyclopropylethynyl looks to interact in a similar fashion as that of efavirenz but with its
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own unique binding interactions. The results shown in Figure 17 gave a positive
reinforcement of the pursuit to synthesize the alkylethynyl sultams.
Table 3 shows the data of efavirenz and the three sultams within the NNIBP of
the mutant strain of RT Y181C (Tyr 181  Cys 181). The first point to notice with the
mutant interaction is that all three sultams have strong interactions with Lys 101 either
being closer or equal to that of efavirenz at 2.31 Å. The presence of cysteine has
changed the interaction of the sultams greatly, although there is a lack of interaction
with cysteine itself with the absence of an aromatic ring in the amino acid residue. The
other interactions occurring throughout the pocket seem to resemble that of efavirenz
relatively closely. With the mutant strain, each sultam shows a hydrogen-bond
interaction with angles roughly between 120 and130 compared to efavirenz at 97.76.
Figure 19 shows the theoretical binding structure of the ethynylcyclopropyl sultam with
efavirenz in the mutant Y181C RT. The sultam is in red and efavirenz is white. The two
have very similar positioning within the NNIBP of the mutant RT. Efavirenz is one of the
few NNRTIs that can still be partially active with the mutant strain, and looking at the
similar bonding of the sultam leads to the possibility that the sultam could be active as
well.
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Tyr 318

Lys 101

Trp 229

Tyr 188

Cys 181

Tyr 183

Figure 19. Efavirenz (white) and cyclopropylethynyl sultam (red) in NNIBP of
mutant RT Y181C.79

The bis-alkylated sultams were too large to perform docking studies in wt RT, but
were able to be docked into the Y181C RT pocket. 79 Table 4 shows the distances of the
sulfonyl and the alkyl groups attached to the alkyne of the bis-alkylated sultams to the
important residues of the Y181C binding pocket. Interestingly, the modeling program did
not show a result of the distance between the mono-alkylated sultams and the Cys 181
residue, but the bis-alkylated compounds are within the distance to be considered a
strong interaction; however, there is a loss of the SO2 to Lys 101 interaction. Figure 20
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shows the shape the bis-alkylated compounds form to within the binding pocket. The
overall confirmation is very different than that of efavirenz leading to the inability to
predict the possible binding accurately.

Table 4. Distances between biscyclopropyl and bis-tert-butylethynyl sultams and
key residues in Y181C rt. CP = cyclopropyl and t-Bu = tert-butyl
bis-tert-butylethynyl
biscyclopropylethynyl
sultam
Residue in Y181C
Distance (Å)
Distance (Å)
Cys 181
SO2
3.96
SO2
2.37
Tyr 183
CP (A)
5.72
t-Bu (A)
7.32
Tyr 188
5.77
5.01
Trp 229
4.33
4.42
Tyr 318
CP (B)
3.75
t-Bu (B)
3.26
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Tyr 318

Lys 101

Trp 229
Tyr 188

Cys 181

Tyr 183
Figure 20. Bis-cyclopropylethynyl sultam (purple) and bis-tert-butylethynyl sultam
(red) in the Y181C binding pocket with nevirapine (white).79

Figure 21 shows the compound (S)-3-(3-cyclopropylphenyl)-2,3-dihydro2,methyl-1,2-benzisothiazole 1,1-dioxide in the NNIBP of wt RT with efavirenz.
Compared to the similar structure of 3-methylphenyl sultam in Figure 18, the
cyclopropylphenyl sultam shows a closer fit to efavirenz. Rings A and B of the sultam
are closer to overlapping the efavirenz Rings A and B, and the cyclopropyl group of the
sultam. Although it is not in the same position, it is in the same area as the cyclopropyl
group of efavirenz, with the cyclopropyl groups essentially competing for the same
space.
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Lys 101

Tyr 188
Trp 229

Tyr 181

Figure 21. 3-Cyclopropylphenyl sultam (red) with efavirenz (green) in NNIBP of wt
RT.

The binding studies give a theoretical insight to the ability for the sultams to
inhibit RT, and in most cases indicate a probable chance of high activity.
I.

CoMFA Modeling
1. CoMFA
Comparative molecular field analysis (CoMFA) is a useful tool in in silico

quantitative structureactivity relationship (QSAR) studies to aid in predicting possible
biological behaviors of new compounds using a method derived from the relationships
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of a set of already tested compounds with known properties. 81 The idea of CoMFA
came from three points of observations in QSAR like studies: most relevant numerical
property values would be shape-dependent, non-covalent interactions produce
observed biological effects, and molecular mechanic force fields, typically steric and
electrostatic forces, account for a variety of observed molecular properties.
CoMFA collects data from field values at lattice intersections of automatically
calculated parameters of energies of sterics (van der Waals) and electrostatic
(coulombic) interactions between the compound of interest and a “probe atom” placed
at various intersections of a regular three-dimensional lattice large enough to surround
all of the compounds in the series (Figure 22).81 The van der Waals values are
dependent on the force field applied (Tripos, MM3, MM4. etc.) and the atomic charges
are dependent on what charges are applied to the series (GasteigerMarsili,
GasteigerHückel, etc.). The probe atom is diagnosed by default with the properties of
an sp3 carbon and a charge +1.0. When the probe atom experiences a steric repulsion
greater than what is called the “cut-off,” the steric interaction is set to the value of that
“cut-off,” and the electrostatic interaction is set to the average of the other molecules’
electrostatic interactions at the same location.81 From here, a partial least-squares
(PLS) method is employed to extract QSAR data from the data table, and a QSAR
equation is generated.
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Figure 22. The CoMFA process.81

After setting the force field and the charges, CoMFA’s most important input
variable in positioning of the molecular model within the lattice is highly dependent on
what is called the “alignment rule,” because of the dependence of the relative interaction
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energies on relative molecular positions. The molecules in the series are to be aligned
together through space in a “field-fit” manner in order to set the molecules in positioning
of the fixed lattice.81 Once the “alignment rule” has been met, the last of the input data is
the known biological activity value of each compound. This is entered into the program
in a table as the log of each value of biological activity. From here, CoMFA outputs data
that includes a cross-validated r2, the “coefficient contour” map displays, and the
desired prediction values of compounds with unknown data.82
2. MM4 Force Field
The minimalization force field applied to the sultams in this project was the
molecular mechanics 4 (MM4) force field. The MM4 force field was developed to
improve upon the calculation of vibrational frequencies, rotational barriers, and various
relatively small errors found in the MM3 force field.83 Since MM3 was already useful and
decent with few substantial errors, it was used as the template for the design of the
MM4 force field. An accurate force field of compounds is dependent on three
moderately coupled parts: structure, vibrational spectra, and the heats of formation. The
MM3 force field was developed in 1989 to improve upon the MM2 force field developed
in 1977 that only gave a good interpretation of organic compounds. From here, the MM3
force field allowed the calculation of vibrational spectra with fair accuracy and thus
allowed the calculation of certain thermodynamic properties. The MM3 force field has
been labeled as a class 2 force field with its use of harmonic terms, explicit diagonal
effects, cubic and higher terms, and explicit off-diagonal elements to the force constant
matrix (mechanical terms). A class 3 force field would take into account these
mechanical terms while also including chemical effects such as electronegativity and
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hyperconjugation. From here, the MM4 force field was developed to improve the MM3’s
insufficient accuracy of vibrational spectra, rotational barriers for congested molecules
low calculations, the lack of vibrational energy being taken into account for heats of
formation calculations, and small improvements on structures of simple compounds on
the whole.84
Following the improvements on the MM3 model, a set of cross terms was added
to the MM4 force field to improve the force field. The cross terms involved were bendtorsion-bend, torsion-improper torsion-improper torsion, and stretch-stretch terms.
These new terms work together to improve upon the method without taking away the
effect of each other. The new terms work to improve the coupled in-plane bending, the
out-of-plane bending, and stretching vibrational frequencies, in that order. 85
3. GasteigerMarsili Charges
Atomic charges can be calculated through several methods in computer
modeling programs by characterizing the atoms by their orbital electronegativies. The
GasteigerMarslili method goes on to include the effect of the connectivities of the
atoms in a molecule to further advance the calculation of charges based on
electronegativity. Using the connectivities, not only are the orbitals of a particular atom
involved in the calculation, but the effect of neighboring orbitals as well, therefore
involving the inductive effect.86
J.

Summary
With the identification of HIV as the causative agent of AIDS, 3 which is one of the

landmark discoveries in the history of medicine, the challenge was put into the hands of
the medicinal chemist to develop therapies to either eradicate 87 or at least limit the
54

development of the virus. By making use of a precise knowledge of the lifecycle of the
HIV virus, a number of points for pharmaceutical intervention were identified, among
them the reverse transcriptase process.23 To this end, medicinal chemists have worked,
using molecular modeling and QSAR studies to design non-nucleoside reverse
transcriptase inhibitors (NNRTIs) that have shown substantial activity against HIV.
These, and a handful of other drugs acting on other points of attack, either alone or in
combination, are today the only successful anti-HIV therapies, given that fact that a
vaccine against the virus remains elusive.88
That which remains to do in the Baker group is to extend the molecular modeling
and CoMFA studies on the binding of a class of non-nucleoside RT inhibitors called
“sultams” to improve both potency and activity toward resistant HIV strains. 72, 79 The
Baker group has developed methods to selectively synthesize specific enantiomers for
a large number of sultams and has developed considerable structurederivatives of 3substituted-1,2-benzisiothiazole 1,1-dioxides. Taking the lead of efavirenz, a successful
drug from Merck and Co., a new set of NNRTIs is planned.
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Chapter II. Statement of the Problem
AIDS is still a large problem throughout the world today, with HIV being the
cause of the epidemic. Many forms of treatment have come along to help reduce the
mortality rate of the disease with inhibition of reverse transcriptase being a popular
method of inhibition. It is our hope that our proposed compounds will be effective
against wt RT and mutant strains of RT. After FlexiDock modeling work performed by
Dr. Kafri, the use of another modeling method called CoMFA is to be used to further aid
in predicting possible activities of the proposed compounds. Using calculations to
analyze compounds with known biological activities, an r2 value, a coefficient of
determination, is to be determined to help predict theoretical EC50 values for the sultams
to be designed and synthesized in this project.
Previous research by Dr. Kafri looked into synthesizing the three bis-alkynyl
compounds shown in Figure 16 along with the three mono-substituted compounds. In
her research, she declares success in the synthesis of 3,3-bis(cyclopropylethynyl)-2,3dihydro-2-methyl-1,2-benzisothiazole

1,1-dioxide,

3,3-bis(cyclobutylethynyl)-2,3-

dihydro-2-methyl-1,2-benzisothiazole 1,1-dioxide, 3,3-bis(tert-butylethynyl)-2,3-dihydro2-methyl-1,2-benzisothiazole 1,1-dioxide, and (S)-3-(tert-butylethynyl)-2,3-dihydro-2methyl-1,2-benzisothiazole 1,1-dioxide, none of which required reduction following the
initial organometallic addition (Scheme 6).
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In addition were also synthesized compounds of complete reduction (S)-3(cyclobutylethyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole
(cyclopropylethyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole

1,1-dioxide
1,1-dioxide.

and

(S)-3-

Evidence

suggests that in the time since Dr. Kafri has left the department, the bis compounds
have degraded, and further studies of her data suggests that the mono tert-butylethynyl
sultam has not been synthesized. This project looks to reproduce her compounds while
also adding to the database the compounds 3-(tert-butylethynyl)-2,3-dihydro-2-methyl1,2-benzisothiazole
benzisothiazole

1,1-dioxide,
1,1-dioxide,

3-(cyclobutylethynyl)-2,3-dihydro-2-methyl-1,23-(cyclopropylethynyl)-2,3-dihydro-2-methyl-1,2-

benzisothiazole 1,1-dioxide, and (S)-3-(3-cyclopropylphenyl)-2,3-dihydro-2-methyl-1,2benzisothiazole 1,1-dioxide, all of which require selective 1,2-reduction of the
intermediate imine.
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In previous research on the sultams, methods for synthesizing the alkylated
sultam in the first step resulted in low yields and without selectivity of a mono or bis
product. This project will work towards the improvement of the methodology of the
addition of a lithiated or Grignard reagent to saccharin or pseudo-saccharin chloride
reaction step of the synthesis to achieve methods with selectivity of one product over
the other in the case of mono- vs. bis-alkynyl derivatives. The purpose of the research
into the novel methodology was to improve the yields of the preferred product over the
undesired side product.
A third issue discussed in this project involved how previous research showed
that the S-enantiomer of the sultam class of NNRTIs as the more active enantiomers,
and the previously discussed Rh catalyst for asymmetric reduction was used to attain
the desired product. However, once the chiral Rh catalyst was applied to the alkynyl
sultams, previous research shows that a 1,4-reduction of the ,-conjugated system
resulted. From this problem, research was performed towards the goal of performing the
1,2-reduction or possibly isolation of the S-enantiomer. Various methods included, other
asymmetric reducing reagents, employing the Luche reduction (a racemic reduction
favoring 1,2- over 1,4-reduction), isolation of the desired S-isomer via chiral resolution
methods, or protection of the alkynes as cobalt derivatives.
The final problem to solve was the development of a procedure for the synthesis
of (S)-3-(3-cyclopropylphenyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1-dioxide, a
compound of compelling interests from its FlexiDock model and CoMFA predictions.
Methods involved looking into performing traditional SimmonsSmith reactions first,
which later would be altered as to form the cyclopropane ring in the last step with an
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iodomethylzincphenoxide reagent. From here, issues arose with the separation of the
(S)-3-(3-vinylphenyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1-dioxide and the final
compound 3-cyclopropylphenyl sultam.
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Chapter III. Results and Discussion
A. CoMFA Modeling
1. Preparing Sultams with Known Activities
Each sultam with known activity was drawn in the Sketch Molecule menu of
SYBYL 8.0. The sultams sketched resembled the structure in Figure 23 where R1 and
R2 are shown in Table 5. Hydrogen atoms were added, and the MM4 force field
minimalization was applied followed by the GasteigerMarsili charges. The structures
were then superimposed onto each other to form a database with the common substructure of (S)-3-phenyl-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1-dioxide, Figure
23, as the aligning model.

Figure 23. Common substructure of sultams with known activities modeled into
SYBYL 8.0. The positions of R1 and R2 are shown in Table 5.
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Table 5. Sultams with known activities, their EC50 and the pEC50 for CoMFA
studies with validation data
sultam

EC50
(uM)

pEC50

R1

R2

phenyl

H

0.471

6.327

m-vinylphenyl
mhydoxymethyl
phenyl
m-CHOphenyl
m-OMs
phenyl
mmethylphenyl
m-Fphenyl

H

0.86

predicted predicted Difference Difference
pEC50
EC50
pEC50
EC50

6.066

6.148
6.524

0.711
0.299

0.179
-0.458

-0.240
0.561

6.04

5.219

5.101

7.925

0.118

-1.885

1.41

5.851

5.726

1.879

0.125

-0.469

1.91

5.719

5.703

1.982

0.016

-0.072

H

0.037
0.179

7.432
6.747

m-Clphenyl

H

0.086

7.066

m-Brphenyl

H

0.074

7.131

m-Iphenyl
omethylphenyl
pmethylphenyl
methylphenyl

H

0.076

7.119

6.821
6.797
7.060
7.170
7.167

0.151
0.160
0.087
0.068
0.068

0.611
-0.050
0.006
-0.039
-0.048

-0.114
0.019
-0.001
0.006
0.008

4.68

5.33

5.589

2.576

-0.259

2.104

1.53

5.815

5.894

1.276

-0.079

0.254

0.12

6.921

7.038

0.092

-0.117

0.028

H
H
H
H

H
H
H
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2. Data Input
A spreadsheet was designed resembling Table 5 with each sultam designed
being represented by a number in a row and its respective EC 50 and calculated pEC50.
The CoMFA interaction energies were calculated for each compound, and a partial least
squares analysis was performed to produce the correlation value, R2. Using a nonvalidation calculation with three components, an R2 value of 0.890 was determined. The
manual for use of CoMFA states that an R2 value above 0.65 and below 0.95 to be
substantial for predictability, with any value above 0.95 as being too ideal to be usable
data.
To test the viability of the R2 value from the known sultam compounds used for
the CoMFA analysis, a cross validation was performed on the same biologically active
compounds shown in Table 5. The cross-validation results produced predicted activities
within a 0.0012.1 micromolar range of the known values. The m-halogenated phenyl
sultams resulted in excellent predictability of the CoMFA analysis with differences in the
nanomolar range. A few cases resulted in larger differences in the micromolar range,
such as the o-methylphenyl sultam, which CoMFA predicted a higher activity for this
compound. The validation results predicted some values to have greater activity in
some cases and lower activity in others; however, the values were without further
analysis deemed generally applicable for calculating predicted activities of novel
compounds.
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3. Preparation of Sultams with Unknown Activities
The sultams to be analyzed for a predicted activity were prepared in a similar
fashion as those with known activities in Section 4 with the MM4 force field,
GasteigerMarsili charges, and the superimposing with a common substructure of 2,3dihydro-2-methyl-1,2-benzisothiazole 1,1-dioxide (Figure 24). They shared the same
common structure of Figure 5, with the R1 and R2 shown in Table 6.

Figure 24. Common sub-structure of novel sultams.

4. Data Output
The data output from the CoMFA analysis produced predicted pEC50 values for
the novel sultams. These values were converted to the EC50 value giving predicted
activities

of

the

sultams. The predicted

most

active

sultam

is the

(S)-3-

cyclopropylethynyl-2,3-dihydro-2-methyl-1,2-benzisothiazole with an EC50 of 0.148 M.
The bis-alkylethynyl compounds were predicted with EC50 values around 0.33 to 0.38
M. These predictions are only a general idea of the activity of the novel sultams. The
CoMFA analysis was comparing mainly sultams with an aryl substituent as compared to
the alkynyl substituents of the novel sultams.
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Table 6. Novel sultams with calculated and predicted EC50 and pEC50 values.
Sultam

EC50(M)

pEC50

R1

R2

cyclopropylethynyl

H

0.148

6.831

cyclopropylphenyl

H

0.167

6.776

cyclopropylethynyl

cyclopropylethynyl

0.333

6.477

tert-butylethynyl

H

0.160

6.795

tert-butylethynyl

tert-butylethynyl

0.344

6.464

cyclobutylethynyl

cyclobutylethynyl

0.378

6.422

B. Synthesis
1. Overview
The original synthetic method to yield the ethynyl sultams resembles that as
designed by Baker and co-workers to synthesize (S)-3-aryl-2,3-dihydro-2-methyl-1,2benzisothiazole 1,1-dioxide, which was expanded from that of Abramovitch et al where
two equivalents of an aryl magnesium chloride or bromide Grignard reagent were
coupled to one equivalent of saccharin to produce the respected 3-(aryl)-1,2benzisothiazole 1,1-dioxide (Scheme 5).69,

70, 74

Using this method, a synthesis was

designed using 2 equivalents of alkynyllithium reagents with saccharin to yield the
desired

3-(alkylethynyl)-1,2-benzisothiazole

1,1-dioxides

(7-1).

From

here,

the

carbonnitrogen double bond would be asymmetrically reduced by the (R,R)[TsDPEN]RhCp* catalyst developed by Baker and co-workers to yield the (S)-364

alkylethynyl)-1,2-benzisothiazole 1,1-dioxide product (7-2). The nitrogen atom would be
deprotonated by cesium carbonate, and the resulting negative charge on the nitrogen
atom would act as a nucleophile towards the methyl iodide producing the methylated
nitrogen

atom

in

the

product

(S)-3-(alkylethynyl)-2,3-dihydro-2-methyl-1,2-

benzisothiazole 1,1-dioxide (7-3) (Scheme 7).

When the project began, methodologies were to be investigated to synthesize
the compounds (S)-3-(cyclopropylethynyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1dioxide, (S)-3-(cyclobutylethynyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1-dioxide,
and (S)-3-(3-cyclopropylphenyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1-dioxide,
as shown respectively, in Figure 25. Furthermore, the project was to also look into
samples developed by Dr. Riyam Kafri (Figure 26), which upon analysis, signs of
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possible degradation may have occurred, and the compounds would need to be
synthesized again to be used for biological testing.79

2. 3-(Alkylethynyl)-1,2-benzisothiazole 1,1-dioxide (10-110-3)
Two issues arose in the above-proposed method to synthesizing the alkylethynyl
sultams. Firstly, the lithiated alkynyl compounds, when reacted with saccharin,
produced the mono-alkynyl sultams in low yield, while also resulting in the production of
bis-alkylated products. The second issue was that the use of the rhodium catalyst for
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the asymmetric reduction would result in 1,4-reduction instead of the desired 1,2reduction. The first problem that will be discussed is the development of a method to
improve the synthesis of mono-alkylethynyl-1,2-benzisothiazole 1,1-dioxide while
limiting the production the bis-alkylethynyl-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide.
As stated previously, when performing the addition of the lithiated alkynes to
saccharin, the yield of the mono-substituted sultam (8-1) was substantially low
compared to the addition of aryl magnesium bromides. The product of the bis-alkylated
product (8-2) was also detected as determined by DARTHRMS and 1H and
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C NMR

spectroscopy (Scheme 8). It was determined that from here a new method was to be
developed that improved the selectivity of the product and the yield of the monosubstituted product. A goal was to also design another method to produce the bissubstituted product in higher yield as well.

As discussed by Abramovitch et al.,74 another compound named 3-chloro-1,2benzisothiazole 1,1-dioxide (saccharin pseudo-chloride) was shown to react with
lithiated alkanes to produce similar compounds. To produce the saccharin pseudo67

chloride (9-1), saccharin was dissolved in 1,4-dioxane, and an excess of thionyl
chloride was added to the solution. A catalytic amount of N,N-dimethylformamide was
added to perform the reaction under Vilsmeier-like conditions (Scheme 8).89 The
reaction was stirred at reflux for two days, and brought back to room temperature. The
reaction mixture was rotary evaporated to remove solvent, and then recrystallized
using hot toluene producing white crystals of the chloro derivative.

The reactivity of the saccharin pseudo-chloride (9-1) was shown to be greater
than that of saccharin itself, which resulted in the production of the bis-alkylated product
in higher yield under the right conditions. From here, methodology was designed to
favor the mono- over the bis-product and another method to favor the bis- over the
mono-product.
In an attempt to produce more of the mono-alkylated product relative to the bisproduct, because of the saccharin pseudo-chloride’s (9-1) higher activity, it was decided
to use 1.5 equivalents of the chloride 9-1 to 1.0 equivalent of the lithiated alkyne.
Furthermore, the reaction was performed by slowly injecting the lithiated alkyne into a
solution of the saccharin pseudo-chloride (9-1) over a period of 1 hour at 78 C. Under
these conditions, the saccharin pseudo-chloride (9-1) always would be at a substantially
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much higher concentration than the lithiated alkyne at cold temperatures, resulting in
the nucleophile to favor a mono-addition over the bis-addition (Scheme 9). This method
on average produced around 60% yield of the desired mono-product when the alkyne
was commercially available in high purity (10-1 (70%) and 10-3 (59%)).
In the case of the cyclobutylethynyl derivative 10-2, the ethynylcyclobutane
precursor was synthesized from 6-chlorohexyne (11-1) with 2 equivalents of n-BuLi
under anhydrous conditions starting at 78 C with warming to room temperature
overnight.90 It was found that the product of that reaction, before work-up, was typically
cyclobutylethynyl lithium (11-2) and was therefore added directly to a solution of 1.5
equivalents of saccharin pseudo-chloride (9-1) (Scheme 10). Due to the boiling point of
ethynylcyclobutane being so close to THF, the purification by distillation of the
compound from THF proved impossible, thus limiting its purity for the lithiation reagent.
Because of the immediate addition of the synthesized lithiated ethynylcyclobutane (112), with the presence of impurities, the percent yield was typically around 15%.

69

In steps taken toward producing the bis-alkylated products, a number of factors
were considered in adjusting the conditions for the synthesis of the mono-alkylated
products in order to reverse the outcome. After performing the steps to produce the
lithiumhydrogen exchange on the alkynes, 0.5 equivalents of saccharin pseudochloride (9-1) were slowly added dropwise to the solution of the lithiated alkyne at 78
C (inverse addition), which was warmed to 10 C over a period of 1 hour (Scheme 12).
This method allowed the lithiated alkyne to be greater in concentration compared to the
saccharin pseudo-chloride (9-1) at all times. After the work-up and column
chromatography, the method produced close to a 70% yield for bis-derivatives 12-1
(69.5%) and 12-3 (88%), while that for 12-2 was lower (15%) due to the impure lithium
reagent as for 10-2.

70

As shown in Mechanism 1, the mono-imine product is postulated to form by the
addition of the alkyne at the electrophilic carbon atom attached to the nitrogen atom
and the chlorine atom, thereby pushing electrons onto the nitrogen atom. From here,
the electrons re-form the double bond resulting in the chlorinecarbon bond breaking
and the Cl- leaving. For the mono-substituted product, work-up with satd NH4Cl is used
to quench any remaining base. The second line in Mechanism 1 shows how the
second equivalent of the alkyne is added to the same carbon atom center pushing the
electrons onto the nitrogen atom once more, but from here, the use of a slightly acidic
work-up protonates the nitrogen atom and ends the reaction. To confirm that this was
how the formation of the bis-alkylated product was proceeding, a reaction was
designed

where

pure

3-cyclopropylethynyl-1,2-benzisothiazole

1,1-dioxide

was

dissolved in dry THF, brought to 78 C, and one equivalent of lithiated
ethynylcyclopropane was added to the solution. Formation of the bis-product was seen
showing how the second equivalent of the lithiated alkyne could add once more in the
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reaction to the same electrophilic center without a need for a proton source such as
water.

As discussed by Abramovitch et al., the methodology for the synthesis of the bisalkylated versus the mono-alkylated product needed improvement.74 Abramovitch et al.
typically produced 10% of the mono-alkylated product and 24% of the bis-alkylated
product by their methods.74 The method employed by Kafri produced around 40% yields
and showed no selectivity in mono- versus bis-product production.79 By the change in
the order and speed of addition, temperature control, and taking advantage of
concentration ratios, the yields of the bis- versus the mono-products were adjusted to
favor one product over the other successfully and in greater yields. At this point, a
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methodology for performing 1,2-reductions on the mono-alkylethynyl sultams would be
investigated.
3.

3-(Alkylethynyl)-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide (16-116-3)
As previously discussed, a paper by Baker and co-workers addressed the design

and synthesis of a novel catalyst employing the ligands as used by Noyori et al. with the
reactivity of rhodium towards the reduction of imines.75,

78

Noyori’s catalyst used

(1S,2S)-p-TsNCH(C6H5)-CH(C6H5)NH2 and various aromatic groups as ligands on
ruthenium chloride as an asymmetric catalyst for hydrogenation of ketones with high
ee.75 Noyori’s catalyst was shown to work on imine double bonds with varying high ee,
however, with long reaction times.75 It was found by Dr. Jianmin Mao, while in Dr.
Baker’s lab, that rhodium-based catalysts showed strong affinity for reactions with
imines.77, 78 The rhodium catalyst performed asymmetric hydrogenation with a 5:2 formic
acidtriethylamine azeotrope on the 3-aryl-1,2-benzisothiazole 1,1-dioxides (13-1) with
high yield and a high ee around 95% (Scheme 13).
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In Dr. Kafri’s research it was found that when used to reduce two of the 3alkylethynyl-1,2-benzisothiazole 1,1-dioxides (10-1 and 10-2), the chiral rhodium
catalyst (Figure 14) would not only reduce the imine bond in a 1,2-reduction fashion, but
also the triple bond due to the ,-conjugated system in these compounds, performing a
complete reduction.79 This would result in the production of 3-alkylethyl-2,3-dihydro-1,2benzisothiazole 1,1-dioxides (14-1) (Scheme 14). However, Dr. Kafri stated that when
the rhodium catalyst was used to reduce 3-(tert-butylethynyl)-1,2-benzisothiazole 1,1dioxide (10-3), the 1,2-reduction was performed to produce 15-1, as shown in Scheme
15.79 As with the bis-alkylated sultams, the material for 15-1 had degraded; therefore,
the synthesis of 15-1 would also be a part of the work performed. Further studies by
performing the reaction and investigating as per Dr. Kafri’s methods did not yield 15-1.
Upon a more detailed investigation of the 1H and
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C NMR of (S)-3-(tert-butylethynyl)-

2,3-dihydro-1,2-benzisothiazole 1,1-dioxide (15-1) doubts in the synthesis of the desired
product arose. This led to the inclusion of compound 10-3, the tert-butyl imine, in the
search of a method to yield only the 1,2-reduction and not the 1,4-reduction for all three
compounds 10-110-3.
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The first attempt to perform the 1,2-reduction was to use a mild reducing agent
such as NaCNBH3 in methanol with the idea that it would not be reactive enough to
perform the 1,4-reduction. However, this, too, would perform the 1,4-reduction while
also performing the racemic reduction resulting in the 50:50 mixture of 3-alkyl-2,3dihydro-1,2-benzisothiazole 1,1-dioxide. Seeing as this was not a desired product, the
method was abandoned.
After further investigation, the Luche reduction, which has been shown to perform
a racemic 1,2-reduction of ,-conjugated ketone systems, was attempted.91 Further
hopes for the application of the Luche reduction was found in a reaction of a patent for
pyrazolyl-amino substituted pyrazines where the conditions for the Luche reduction
were applied to an imine bond adjacent to an aromatic ring. 92 From here, the Luche
reduction was applied to compound 10-1 first to test usefulness of the reaction. Results
found that the Luche reduction can also be applied to an imine functionality with ,conjugation to give an alkyne in a heterocyclic system with high yield of approximately
75% (Scheme 16). This was unique at the time, because the only application of the
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Luche reduction to imines involved the imine in conjugation with aromatic rings instead
of alkynes or alkenes.
Due to the lower reactivity of the nitrogen atom in an imine bond, when compared
to the oxygen in a carbonyl bond, the method involved reacting the 3-alkylethynyl-1,2benzisothiazole 1,1-dioxides (10-110-3) with 1.5 equivalents of CeCl3 for 1 hour at
room temperature before addition of 1.5 equivalents of NaBH4 in 100% ethanol at 0 C.
The reaction was stirred at 0 C for 30 minutes before warming to room temperature
and stirring for one hour. It was later investigated to attempt the Luche reduction with
CeCl37H2O, a cheaper alternative to the anhydrous CeCl3, with positive results. Since
the application of the Luche reduction in this project, a paper was published in 2012
discussing the procedure of using Luche reduction conditions on hexaazamacrocycleslike compounds to reduce conjugated imines, but again, the conjugation was with
aromatic rings instead of an alkyne or alkene that risked the chance be reduced in a 1,4
fashion.93 This gives evidence that the application of the Luche reduction to ,conjugated imines to perform 1,2-reductions as a novel methodology.
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Upon the synthesis of racemic 16-3, a comparison of its NMR spectra to those of
Dr. Kafri for the purported 15-1, it was concluded that the compound had not been
synthesized. In Dr. Kafri’s
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C spectrum of 15-1, the carbon peak of the C=N is still

present; furthermore, in her 1H spectrum, there is a singlet proton peak around 6.2 ppm,
which, the proton spectrum for 16-3 shows two proton peaks at 4.81 ppm for the
hydrogen atom on the nitrogen atom in 16-3, and 5.41 ppm for the hydrogen atom on
the carbon atom adjacent to the nitrogen.79
As discussed previously, this method produced a high yield of the racemic
products (16-116-3), and a procedure was sorely needed for synthetically producing
the pure (S)-enantiomer of the desired 3-(alkylethynyl)-2,3-dihydro-1,2-benzisothiazole
1,1-dioxides.
From here, methods were explored to attempt coupling of the now 3-alkylethynyl2,3-dihydro-1,2-benzisothiazole 1,1-dioxides (16-116-3) with an amino acid with
defined stereochemistry as an attempt to induce a chiral resolution that can be used to
manipulate the presence of diastereomers in column separations. The amino acid Lphenylalanine was chosen for coupling with the nitrogen atom of the heterocycle in
attempts to form a peptide bond.
The first attempt in the project for coupling the nitrogen atom of the sulfonamide
functionality was to look at the use of amino acid coupling reagents. According to
Backes and Ellman, the coupling reagent PyBOP, has shown substantially good results
when coupling Ellman’s modification of Kenner’s sulfonamide linker (Figure 27) resin
with a Boc-protected L-phenylalanine with a yield of 90% in DCM at 20 C with i77

Pr2EtN as the base.94 When compared to other peptide coupling agents, Ellman’s
modification has also been used by Marcaurelle and Bertozzi to synthesize deptericin
and by Mende and Seitz to synthesize peptide -thioesters with protection by Fmoc
instead of Boc.95, 96 The idea was investigated to look into the idea of a heterocyclic
sulfonamide reacting under similar conditions as the primary alkanylsulfonamide in the
resin. The same conditions were maintained for the first attempt, and 3cyclopropylethynyl-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide (16-1) was reacted with
L-Boc-Phe-OH with PyBOP as the coupling reagent (Scheme 17). Using the DARTMS, evidence of the mass of the product appeared, but subsequent column
chromatography produced very little of the coupled product. Alterations of time and
temperature also proved to not yield a substantial amount of product, leading to a
pursuit of alternate methods.
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A different approach was attempted when several papers presented the idea of
reacting the 3-alkylethynyl-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide (16-116-3) with
a base to deprotonate the nitrogen, which would then react with an acyl chloride to form
the peptide bond.97, 98 Oppolzer et al. performed various methods of acylating either (S)3-methyl-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide or camphorsultam with either acyl
chlorides or with trimethylaluminum and an ester.97 One attempt used the (S)-methyl
sultam 19-1 with propionyl chloride (Scheme 19). Seeing as Oppolzer used a sultam
very similar to 16-1 instead of a primary solid-phase sulfonamide like those in Figure 25,
the same method was attempted with racemic 3-cyclopropylethynyl-2,3-dihydro-1,2benzisothiazole

1,1-dioxide

(16-1)

with

N-Cbz-L-phenylalanine

acyl

chloride.

Triethylamine was used to deprotonate the nitrogen atom of the heterocycle, which
would then be expected to attack the carbonyl carbon of the acyl chloride producing the
peptide bond (Scheme 18).

79

The coupling with the use of the acyl chloride of the amino acid and the racemic
3-cyclopropylethynyl-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide (16-1) gave no positive
results. When compared with the method of Oppolzer et al., the sulfonamide 19-1
already had defined stereochemistry with only a methyl group at the 3-position as
compared to the racemic cyclopropylethynyl substituent.97 Furthermore, Oppolzer et al.
performed the coupling with propionyl chloride to form 19-2 as opposed to the bulkier NCbz-L-phenylalanine acyl chloride (Scheme 19). It is believed that the sterics of the
racemic ethynyl sultam compared to the S methyl sultam and the sterics of the Cbzphenylalanine to the propionyl chloride prohibited the reaction from occurring.
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From here, a look into other possibilities for performing the amino acid coupling
with the racemic 3-cyclopropylethynyl-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide (16-1)
was investigated to discover that Oppolzer and co-workers and various other groups
also performed the acylation with the use of trimethylaluminum to couple sulfonamides
with the carbonyl of an ester.99-103 To achieve the ester of the N-Cbz-L-phenylalanine,
the Cbz protected amino acid was reacted with thionyl chloride in methanol. From here,
the sultam was reacted with trimethylaluminum in anhydrous toluene under argon
followed by the N-Cbz-L-phenylalanine methyl ester to attempt to synthesize 20-1
(Scheme 20).102

81

As with the use of the acyl chloride, this reaction was not successful, with
theories believing it was also because of steric hindrance. It was decided to attempt the
same procedure with varying protecting groups on the nitrogen atom of the amino acid.
Of the protecting groups attempted were a Boc-group, dibenzyl-, and methyl- and
benzyl-protected amines. The method failed to produce positive results in any of the
varying compounds, except the Boc-protected group did react, however, not at the
methyl ester site as shown by NMR analysis. The first indication of the product not
occurring at the methyl ester was the presence of a single methyl peak integrating to 3H
as compared to the integration of the single proton in the sultam ring. Furthermore,
using 2-D NMR analysis, it was determined that a peptide bond was formed at the
carbonyl carbon atom of the Boc protecting group because the hydrogen on C3 in the
sultam ring correlated to a carbonyl carbon. The carbonyl carbon did not show a
correlation to the CH2 group in the phenylalanine as it should if the carbonyl were
bonded to the nitrogen atom was from the methyl ester carbonyl. Therefore, the reaction
occurred at the Boc carbonyl and the tert-butoxide group acted as a leaving group,
producing the sulfonylurea sultam 21-1 (Scheme 21).
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In the end, it seemed the use of L-phenylalanine, protected or not, would not
couple to the racemic 3-cyclopropylethynyl-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide
(16-1). The issue of sterics arises with the reasoning of the coupling not occurring. In
the works cited,97, 98, 101-103 the authors either used a sultam with a defined stereocenter
with only a methyl substituent versus our racemic cyclopropylethynyl group, or an
alkanesulfonamide. Most of the authors also used a group for the acylation that was not
itself defined with stereochemistry but rather small and/or flat near the acylating
carbonyl.
From here, different methods were considered for reducing the imine bond
without affecting the triple bond. The use of a compound nicknamed BINAL-H (R isomer
in Figure 26) by Noyori, comprised of reacting LAH with either the R or S isomer of 2,2’dihydroxy-1,1’-binapthol and a simple alcohol (MeOH or EtOH) was considered.104
Noyori et al. found that BINAL-H with ethanol could reduce various ketones
asymmetrically with high ee under cold conditions. When applied to an ,-conjugated
system, BINAL-H showed a preference for asymmetric reduction while also performing
the 1,2-reduction over the 1,4-reduction. BINAL-H has been applied to the asymmetric
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reduction of phosphinyl imines, which gave hope to it working on the cyclic sulfonyl
imine.105 It was with this knowledge that the method and reagent would be applied to
the reduction of 3-cyclopropylethynyl-1,2-benzisothiazole 1,1-dioxide (10-1) (Scheme
22). After several attempts, the analysis of the results of the reaction in Scheme 22
showed that no reaction took place. Conditions were altered to longer reaction times
and/or warmer conditions than discussed in the Noyori paper, which also yielded
negative results.

The next attempt was to use Co2(CO)8 as a protecting group on the alkyne. Upon
reacting the 3-cyclopropylethynyl-1,2-benzisothiazole 1,1-dioxide (10-1) with Co2(CO)8,
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the complex 23-1 with the alkyne was formed according to what appeared as
broadening of peaks in the NMR due to the presence of the cobalt that matched with the
proton shifts of the cyclopropylethynyl sultam proton spectrum (Scheme 23).106-108 After
seeing the presence of the cobalt complex, the asymmetric reduction was attempted
with the chiral rhodium catalyst designed by Baker and co-workers.78 The reaction
appeared to occur only by evidence in the spectrum from the DARTMS with a trace of a
+

H m/z of 234, the mass of 16-1 without the presence of the cobalt protecting group.

Column chromatography failed to produce a tangible amount of pure material. Looking
at the 3-D shape of the cobalt-complexed sultam (Figure 29), the three carbonyl groups
on the cobalt tend to point in various directions of the structure leading one to believe
that they could cause steric interference with the ligands of the rhodium catalyst, thus
preventing interaction of the nitrogen atom to rhodium. At this point a new method was
pursued.

85

Figure 29. Compound 23-1, the cyclopropylethynyl sultam with the alkyne
protected with the cobalt carbonyl complex.

After a search through the literature, one paper by Corey and co-workers showed
the use of a chiral oxazaborolidine with catelcholborane to perform the 1,2-reduction on
,-ynones asymmetrically with high ee without affecting the triple bond.109, 110 With the
Luche reduction occurring primarily on ketones, but also being a feasible method for the
reduction of ,-conjugated imines (Scheme 16), the use of the oxazaborolidine was
applied to the reduction of the sultam as well. The catalytic oxazaborolidine 24-1 was
prepared from (S)-,-diphenyl-2-pyrrolidinemethanol and Me3SiCH2B(OH)2. It was
reacted with the cyclopropylethynyl sultam 10-1 with catelcholborane at 78 C to room
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temperature over night (Scheme 24). After work-up and column chromatography, NMR
spectra and DARTMS indicated a 20% yield for the reduced sultam 24-2, and the triple
bond was not affected, therefore the 1,2-reduction occured. To test for the asymmetric
reduction the sample was analyzed with a polarimeter to assess the optical activity.
Polarimetery at multiple wavelengths showed no rotation, leading one to believe there
was no optical activity; therefore, the reduction occurred, but not asymmetrically. This
method was no longer pursued as it performed the same racemic reduction as the
Luche reduction but lower yield.

After the above-mentioned attempts had been ruled out as viable methods for a
selective 1,2-asymmetric reduction, it was decided to rely on the Luche reduction and to
evaluate the biological activity of the racemic mixtures. Once the biological activity data
are collected, if the data seems worth pursuing the pure enantiomers, the use of chiral
columns for HPLC will be investigated for the purification of the enantiomers. As of this
time, some limited chiral separations have been attempted using the available ChiralCel
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D column, which was used in the Baker group to separate the racemic mixtures of the
3-methylphenyl and similar derivatives by the original method, and a ChiralCel AD
analytical chiral column. No meaningful separations were achieved. More extensive
work using a set of chiral columns, followed by selective (and expensive)
semipreparative columns would be necessary.
Mechanistically, the Luche reduction proceeds by the lone pair on the nitrogen
atom forming a complex with the CeCl3, resulting in the carbon in the imine bond
becoming more electrophilic. Furthermore, the presence of the ethanol causes the
sodium borohydride to become a harder nucleophile by replacing the hydrides with
ethoxide groups. From here, the hydride adds the hydrogen to the carbon of the imine
bond pushing electrons to the nitrogen atom, where after work-up the product is formed
(Mechanism 2).

88

4. 3-Alkylethynyl-2,3-dihydro-3,methyl-1,2-benzisothiazole 1,1-dioxide and 3,3bis(alkylethynyl)-2,3-dihydro-3-methyl-1,2-benzisothiazole 1,1-dioxide (25125-6)
The final step for the product of the mono-alkylethynyl sultams (25-125-3),
including the bisalkylated-products (25-425-6), involved methylating the nitrogen atom.
The process involved the use of the inorganic base Cs2CO3 in an organic solvent in
which it was soluble, acetonitrile or N,N-dimethylformamide. The base deprotonates the
nitrogen atom, where after the addition of iodomethane, the electrons attack the carbon
in the methyl group displacing the iodo group, resulting in the N-alkyl product (Scheme
25).
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5. (S)-3-(3-Cyclopropylphenyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1dioxide (26-4)
Original methods to synthesize compound 26-4 involved initially performing the
SimmonsSmith cyclopropanation on 3-bromostyrene. This was performed via a
traditional SimmonsSmith method with a zinccopper couple and diiodomethane. The
cyclopropanation occurred as evidenced by the presence of the mass of the product in
a GC/MS spectrum; however, upon attempts to form the organometallic form of the
compound (lithiated or Grignard reagent), the organometallic was not formed. Past
results showed use of n-BuLi possibly opened the cyclopropane ring or formed a
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dimeric linked version of the compound, and evidence suggests that the Grignard
reagent, 3-cyclopropylphenylmagnesium bromide was never formed. From here, it was
decided to attempt the cyclopropanation reaction in the last step of the synthesis to 264.
The method for preparing 3-(3-vinylphenyl)-1,2 benzisothiazole 1,1-dioxide (26-1)
follows a method similar to that designed by Baker and co-workers, which resembles
that of Abramovitch et al.74 While a Grignard reagent of 1.0 equivalent of 3bromostyrene is synthesized with magnesium turnings, a solution of 0.9 equivalents of
saccharin in THF is reacted with 0.9 equivalent of phenylmagnesium bromide to
deprotonate the nitrogen atom of saccharin. Once one equivalent of the 3-vinylphenyl
magnesium bromide was prepared, it was added to the deprotonated solution of
saccharin to act as a nucleophile at the carbonyl carbon, and the product was formed
after work-up followed by column chromatography. Compound 26-1 was obtained in a
62.2% percent yield (Scheme 26, 26-1).35
The asymmetric reduction was carried out with the chiral rhodium catalyst
developed by Baker and Mao as it had produced high yields and high ee values in the
past on various other derivatives of the 3-phenylsultams.78 The compound 26-1 was
dissolved in dry DCM, and the catalyst was added with a ratio of 200:1 S:C. An
azeotrope of 5:2 formic acid to triethylamine was added to act as the hydride source,
and after a short reaction time of 30 min to 1 h, the reaction was complete and workedup the compound (S)-3-(3-vinylphenyl)-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide (262) was yielded after column chromatography in 93% yield (Scheme 26).
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The nitrogen atom was methylated as discussed in previous methods with
Cs2CO3 and iodomethane in acetonitrile to give 26-3 at 39% yield (Scheme 26).
The vinyl group on 26-3 was reacted under SimmonsSmith conditions to form a
cyclopropyl ring at the 3-position of the phenyl ring. The first attempt was tried with the
standard SimmonsSmith method using a copperzinc couple in THF with CH2I2 as it
was conducted on 3-bromostyrene. This method yielded little product, leading to a
search for other methods. Charette et al. have reported the use of various phenoxides
with diethyl zinc and diiodomethane to synthesize an iodomethylzinc phenoxide as a
cyclopropanating reagent.111 The paper discussed several phenols with halides in the
ortho and para positions as being effective reagents, along with pentafluorophenol
having similar reactivity to perform the cyclopropanation on styrene.111 Following this
lead, pentafluorophenol was reacted with diethylzinc, followed by CH2I2, to produce the
cyclopropanating reagent that was then added to a solution of compound 26-3 in dry
DCM and allowed to react for two days producing 26-4 in 53% yield. (Scheme 26).
An issue arose with the purification of 26-4 in that the rf values of 26-4 and 26-3
are identical under various solvent system methods. By analysis of NMR integration and
HPLC, the purity of 26-4 appears to be around 90%, and this is adequate enough for
biological analysis as the biological activity of 26-3 is already known. Compound 26-4 is
characterized as a mixture of ca. 9:1 26-4:26-3.
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Chapter IV. Experimental Procedures

General
All reactions were monitored by thin-layer chromatography (TLC). Adsorption
chromatography was carried out using Sorbent Technologies silica gel products: (a)
TLC on 0.2 mm aluminum-backed plates, (b) column chromatography using 60200 m
mesh silica gel. Visualization of the TLC plates was by 254 nm UV light and by dipheat
development using a p-anisaldehydesulfuric acid reagent.112 All reactions were carried
out under a nitrogen atmosphere.
For every procedure involving dry solvents (THF, DCM, DMF, CH3CN), solvents
were dried using alumina columns in a PureSolv system, with THF also being distilled
from sodiumbenzophenone ketyl, and DMF was distilled from calcium carbonate and
stored in a nitrogen-purged flask with 4 Å molecular sieves.
n-butyllithium was purchased from SigmaAldrich as 2.5 M in hexanes, but was
titrated with a solution of diphenylacetic acid in dry THF to determine the molarities
shown in the procedures.113
All NMR spectroscopy was performed on Varian 500-MHz and 125-MHz NMR
instrument in CDCl3. Chemical shifts (-values) are reported downfield from
tetramethylsilane (TMS). Mass spectrometry was performed with a JEOL AccuTOF
Direct Analysis in Real Time (DART) Mass Spectrometer.
All glassware and stir bars were dried in an oven overnight at 150 C, and cooled
in a desiccator before use in reactions.
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Synthesis of 3-chloro-1,2-benzisothiazole 1,1-dioxide (9-1)
In a large 1-L round-bottom flask was added 55.2325 g (0.301520 mol) of saccharin
dissolved 250 mL of 1,4-dioxane. Approximately 90.0 mL (1.25 equiv) of SOCl2 was
added with 4.0 mL of DMF as a catalyst. The reaction was stirred at reflux for 3 days. It
was concentrated under vacuum and recrystallized in hot toluene. 1H NMR:  7.807.95
(4H, m, ArH);

C NMR:  122.44, 125.10, 129.86, 134.46, 134.97, 140.51 (Ar), 166.11
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(NCCl); DARTHRMS: Calcd for C7H4ClNO2S m/z 200.96513; found [M + H]+ m/z
201.97317 (calcd m/z 201.97295).89, 114
Synthesis of 3-(cyclopropylethynyl)-1,2-benzisothiazole 1,1-dioxide (10-1)
In a dry flask was dissolved 0.5656 mg (8.557 mmol) of ethynylcyclopropane (Organic
Technologies) in 10 mL of dry THF. The solution was stirred and cooled to –78 °C
under a nitrogen atmosphere. One equiv of 2.3 M n-BuLi solution in hexanes (3.720
mL) was added via syringe. The reaction was left to stir for 4 h at –78°C. A second
solution of dry THF and 2.5900 g (12.845 mmol, 1.5011 equiv) of 3-chloro-1,2benzisothiazole 1,1-dioxide (9-1) was cooled to a temperature of –78 °C under a
nitrogen atmosphere. It was at this time that the lithiated alkyne solution was added
dropwise via syringe to the benzisothiazole solution over a period of 1 h at 78 C.
After the addition was complete, the reaction was left to stir at –78 °C for 1 h, at which
time it was quenched with satd aq NH4Cl at –78 °C. The mixture was left to warm to
room temperature. The product was extracted with Et2O in a separatory funnel, and the
organic layer was dried with anhyd MgSO4, vacuum filtered, and rotary evaporated.
The desired product was purified on two separate silica gel columns. The first elution
used a 3:1 mixture of Et2O to hexane. This method separated the mono- and bis95

formations of the product effectively; however, some compounds coeluted with the
mono-substituted product in this method. The second column was eluted with a 3:1
mixture of DCM to hexane to purify the desired product at 1.3868 g (70.111% yield). 1H
NMR:  1.091.25 (4H, m, CHCH2), 1.641.73 (1H, m, CHCH2), 7.727.78 (3H, m,
ArH), 7.837.94 (1H, m, ArH);

C NMR:  0.80 (CHCH2), 11.01 (CHCH2), 68.51 (CC),
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116.09 (CC), 122.06, 124.94, 131.60, 133.76, 133.96, 138.62 (Ar), 156.62 (C=N);
DARTHRMS: Calcd for C12H9NO2S m/z 231.27036; found [M + H]+ m/z 232.04424
(calcd m/z 232.04322).
Synthesis of 3-(cyclobutylethynyl)-1,2-benzisothiazole 1,1-dioxide. (10-2)
In a dry flask was dissolved 665.1 mg (5.705 mmol) of 6-chloro-1-hexyne (11-1)
(SigmaAldrich) in 10 mL of dry THF. The solution was stirred and cooled to –78 °C
under a nitrogen atmosphere. Two equiv of 2.3 M n-BuLi solution in hexanes (5.209
mL) were added dropwise via syringe over 20 min. After addition was complete, the
reaction stirred at –78 °C for an additional 20 min, whereupon it was brought to room
temperature and stirred under nitrogen overnight. The next day, a second solution of dry
THF and 1.7844 g (1.5512 equiv, 8.8499 mmol) of 3-chloro-1,2-benzisothiazole 1,1dioxide (9-1) was cooled to a temperature of –78 °C under a nitrogen atmosphere, and
the lithiated ethynylcyclobutane (11-2) solution was added dropwise over 1 h. After
standing for 1 h at –78 °C under a nitrogen atmosphere, the solution was quenched with
satd aq NH4Cl at –78 °C. The biphasic mixture was extracted with Et2O, and the organic
layer was separated and dried with anhyd MgSO4, vacuum filtered, and rotary
evaporated. The desired product was purified on silica gel chromatography by eluting
with a 3:1 mixture of Et2O to hexane, followed by a second silica gel chromatography by
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eluting with 3:1 mixture of DCM to hexane to give the desired product at 245.1 mg
(17.51% yield).

H NMR:  2.002.15 (2H, m, CH2CH2CH2), 2.322.42 (2H, m,

1

CHCH2CH2), 2.442.52 (2H, m, CHCH2CH2), 3.413.48 (1H, m, CH2CHCH2), 7.737.78
(3H, m, ArH), 7.867.89 (1H, m, ArH);

C NMR:  19.45 (CH2CH2CH2), 25.61
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(CH2CHCH2), 29.33 (CHCH2CH2), 73.45 (CC), 114.30 (CC), 122.18, 125.04, 131.34,
133.86, 133.99, 138.71 (Ar), 156.81 (C=N) DARTHRMS: Calcd for C13H11NO2S m/z
245.29694; found [M + H]+ m/z 246.05816 (calcd m/z 246.05887).
Synthesis of 3-(tert-butylethynyl)-1,2-benzisothiazole 1,1-dioxide (10-3)
In a dry flask was dissolved 405.9 mg (4.941 mmol) of 3,3-dimethylbutyne
(SigmaAldrich) in 10 mL of dry THF. The solution was stirred and cooled to –78 °C
under a nitrogen atmosphere. One equiv of 2.5 M n-BuLi solution in hexanes (1.98 mL)
were added via syringe. The reaction was left to stir for 4 h at 78 C. A second
solution of dry THF and 1.992 g (9.882 mmol, 2.000 equiv) of 3-chloro-1,2benzisothiazole 1,1-dioxide (9-1) was cooled to a temperature of –78 °C under a
nitrogen atmosphere, and the lithiated alkyne solution was added dropwise via syringe
to the benzisothiazole solution over 20 min.

After the addition was complete, the

reaction was left to stir at –78 °C for 1 h, at which time it was quenched with satd aq
NH4Cl at –78 °C. The mixture was left to warm to room temperature whereupon the
product was extracted with Et2O. The mixture was then separated in a separatory
funnel, and the organic layer was dried with anhyd MgSO4, vacuum filtered, and rotary
evaporated. The desired product was purified on silica gel chromatography by eluting
with a 3:1 mixture of Et2O and hexane to purify the desired product to give 719.9 mg
(58.99% yield). 1H NMR:  1.46 (9H, s, C(CH3)3), 7.727.78 (3H, m, ArH), 7.857.93
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(1H, m, ArH);

C NMR:  28.76 (C(CH3)3), 29.91 (C(CH3)3), 71.68 (CC), 118.76 (CC),
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122.26, 125.00, 131.44, 133.73, 133.92, 138.85 (Ar), 156.79 (C=N) DARTHRMS: Calcd
for C13H13NO2S m/z 247.31282; found [M + H]+ m/z 248.07567 (calcd m/z 248.07452).
Synthesis of 3-(cyclopropylethynyl)-2,3-dihydro-1,2-benzisothiazole 1,1dioxide
(16-1)
In a dry flask, 0.9651 g (4.178 mmol) of 3-(cyclopropylethynyl)-1,2-benzisothiazole 1,1dioxide (10-1) was dissolved in 100% EtOH at room temperature. While stirring, 2.326
g (6.242 mmol, 1.494 equiv) of CeCl3•7H2O was added to the solution with stirring for 2
h at room temperature. After 2 h, 0.2305 g (6.093 mmol, 1.458 equiv) of NaBH4 was
added to the solution at room temperature with stirring for 3 h.

The reaction was

worked up with DOWEX-50 in [H+] form and stirred for 1 h. The resin was filtered off,
and the EtOH was rotary evaporated off leaving a solid. The solid was dissolved in
DCM, and was washed with H2O (3  10 mL). The organic layer was dried with anhyd
MgSO4 and filtered. The solvent was rotary evaporated, and the desired product was
purified on silica gel chromatography by eluting with a 4:1 mixture of DCM and hexane
to purify the desired product to give 0.5660 g (58.14% yield). 1H NMR:  0.690.72 (2H,
m, CHCH2CH2), 0.780.83 (2H, m, CHCH2CH2), 1.231.30 (1H, m, CH2CHCH2), 4.99
(1H, s, NH), 5.37 (1H, d, J = 5.5 Hz CHNH), 7.527.55 (2H, t, ArH), 7.637 (1H, t, J = 7.5
Hz, ArH), 7.74 (1H, d, J = 8.0 Hz, ArH);

C NMR:  -0.47 (CHCH2), 8.39 (CH2CH),
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49.02 (CHNH), 69.92 (CC), 90.57 (CC), 121.06, 124.91, 129.72, 133.45, 135.06, 138.37
(Ar) DARTHRMS: Calcd for C12H11NO2S m/z 233.05105; found [M + H]+ m/z 234.05850
(calcd m/z 234.05887).
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Synthesis of 3-(cyclobutylethynyl)-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide
(16-2)
In a dry flask, 117.2 mg (0.4763 mmol) of 3-(cyclobutylethynyl)-1,2-benzisothiazole 1,1dioxide (10-2) was dissolved in 100% EtOH at room temperature. While stirring, 226.2
mg (0.7145 mmol, 1.500 equiv) of CeCl3•7H2O was added to the solution, and the
mixture was stirred for 2 h at room temperature. The reaction was then cooled to 0 C,
and 37.3 mg (0.986 mmol, 2.07 equiv) of NaBH4 was added to the solution at 0 C, and
the mixture was stirred for 30 min. The reaction was brought to room temperature and
stirred for an additional 1 h, at the end of which time it was worked up with DOWEX-50
in [H+] form and stirred for 1 h. The resin was filtered off, and the EtOH was rotary
evaporated off leaving a solid. The solid was dissolved in DCM, and was washed with
H2O (3  10 mL). The organic layer was dried with anhyd MgSO4 and filtered. The
solvent was rotary evaporated, and the desired product was purified on silica gel
chromatography by eluting with a 4:1 mixture of DCM to hexane to purify the desired
product to give 87.3 mg (74.1% yield). 1H NMR:  1.821.97 (2H, m, CH2CH2CH2),
2.012.14 (2H, m, CHCH2CH2), 2.162.30 (2H, m, CHCH2CH2), 3.04 (1H, quintet, J =
8.5 Hz, CH2CHCH2), 4.97 (1H, s, CHNH), 5.44 (1H, s, CHNH), 7.507.56 (2H, m, ArH),
7.65 (1H, t, J = 8.0 Hz, ArH), 7.74 (1H, d, J = 7.0, ArH);

C NMR:  18.99
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(CH2CH2CH2), 24.44 (CH2CHCH2), 29.26 (CHCH2CH2), 29.28 (CHCH2CH2), 48.69
(CHNH), 75.30 (CC), 90.94 (CC), 120.81, 124.76, 129.50, 133.27, 134.86, 138.25 (Ar);
DARTHRMS: Calc for C13H15NO2S m/z 247.06670; found [M + H]+ m/z 248.07540
(calcd m/z 248.07452).
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Synthesis of 3-(tert-butylethynyl)-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide (163)
In a dry flask, 315.5 mg (1.277 mmol) of 3-(t-butylethynyl)-1,2-benzisothiazole 1,1dioxide (10-3) was dissolved in 100% EtOH at room temperature. While stirring, 713.9
mg (1.916 mmol, 1.500 equiv) of CeCl37H2O was added to the solution, and the
mixture was stirred for 2 h at room temperature. After 2 h, 72.5 mg (1.92 mmol, 1.50
equiv) of NaBH4 was added to the solution at room temperature, and stirring continued
for 3 h. The reaction was worked up with DOWEX-50 in [H+] form and stirred for 1 h.
The resin was filtered off, and the EtOH was rotary evaporated off leaving a solid. The
solid was dissolved in DCM and was washed with H2O (3  10 mL). The organic layer
was dried with anhyd MgSO4 and filtered. The solvent was rotary evaporated, and the
desired product was purified on silica gel chromatography by eluting with 3:1 DCM to
petroleum ether to give the purified desired product at 238.5 mg (74.9% yield). 1H NMR:
 1.22 (9H, s, C(CH3)3), 4.81 (1H, s, NH), 5.41 (1H, d, CHNH), 7.537.56 (2H, t, ArH),
7.647.67 (1H, td, ArH), 7.75 (1H, d, ArH);

C NMR:  27.59 (C(CH3)3), 30.46,
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(C(CH3)3), 48.86 (CHNH), 73.14, (CC), 95.77 (CC), 120.93, 124.78, 129.58, 133.33,
135.24, 138.86 (Ar); DARTHRMS: Calc for C13H15NO2S m/z 249.08235; found [M + H]+
m/z 250.08992 ( calcd m/z 250.09017).
Synthesis of 3-(cyclopropylethynyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1dioxide (25-1)
In a dry flask, 139.0 mg (0.5958 mmol) of 3-(cyclopropylethynyl)-2,3-dihydro-1,2benzisothiazole 1,1-dioxide (16-1) was dissolved in dry acetonitrile. The temperature
was brought to 0 C, and 581.0 mg (1.788 mmol, 3.001 equiv) of Cs2CO3 was added,
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followed by dropwise addition of 0.19 mL (3.1 mmol, 5.1 equiv) of CH3I. After 45 min at
0 C, the ice bath was removed and the reaction was stirred at room temperature for 2
h. The solution was quenched with satd aq NH4Cl and extracted with EtOAc. The
organic layer was washed with H2O (2  15 mL) and a solution of brine. The organic
layer was separated, dried with anhyd MgSO4, and rotary evaporated. The desired
product was purified on silica gel chromatography with an elution of 2:1 petroleum ether
to EtOAc to give the desired product at 104.8 mg (71.15% yield). 1H NMR:  0.660.72
(2H, m, CHCH2), 0.740.83 (2H, m, CHCH2), 1.221.31 (1H, m, CHCH2), 2.95 (3H, s,
NCH3), 5.01 (1H, s, CHN), 7.527.77 (4H, m, ArH);

C NMR:  -0.61 (CHCH2), 8.51
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(CHCH2), 27.67 (NCH3), 54.37 (CHNCH3), 68.40 (CC), 91.44 (CC), 121.13, 124.72,
129.66, 133.10, 134.02, 135.47 (Ar); DARTHRMS: Calcd for C13H13NO2S m/z
247.31282; found [M + H]+ m/z 248.07506 (calcd m/z 248.07452).
Synthesis of 3-(cyclobutylethynyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1dioxide (25-2)
In a dry flask, 181.8 mg (0.7351 mmol) of 3-(cyclobutylethynyl)-2,3-dihydro-1,2benzisothiazole 1,1-dioxide (16-2) was dissolved in dry acetonitrile and brought to 0 C.
Once at 0 C, 726.6 mg (3.041 equiv, 2.236 mmol) of Cs2CO3 was added, followed by
dropwise addition of 0.23 mL (5.0, equiv, 3.7 mmol) of CH3I. After 45 min at 0 C, the
ice bath was removed and the reaction stirred for 3 h. The solution was quenched with
satd aq NH4Cl and extracted with EtOAc. The organic layer was washed with H2O (2 
15 mL) and a brine solution. The organic layer was dried with anhyd MgSO4, filtered,
and rotary evaporated. The desired product was purified on silica gel chromatography
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by eluting with 2:1 petroleum ether to EtOAc to give the desired product at 141.3 mg
(73.56%). 1H NMR:  1.861.98 (2H, m, CH2), 2.082.16 (2H, m, CH2), 2.242.30 (2H,
m, CH2), 2.98 (3H, s, NCH3), 3.033.09 (1H, m, CH2CHCH2), 5.08 (1H, s, NCH),
7.537.58 (2H, m, ArH), 7.65 (1H, td,J = 5 Hz, J = 1.25, ArH), 7.78 (1H, d, J = 10 Hz,
ArH);

C NMR:  19.22 (CH2CH2CH2), 24.76 (CH2CHCH2), 27.71 (NCH3), 29.67
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(CHCH2CH2), 54.42 (NCH), 73.98 (CC), 91.92 (CC), 121.15, 124.73, 129.65, 133.10,
134.05, 135.05 (Ar); DARTHRMS: Calcd for C14H15NO2S m/z 261.33940; found [M +
H]+ m/z 262.09133 (calcd m/z 262.09017).
Synthesis of 3-(tert-butylethynyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1dioxide (25-3)
In a dry flask, 238.6 mg (0.9570 mmol) of 3-(t-butylethynyl)-2,3-dihydro-1,2benzisothiazole 1,1-dioxide (16-3) was dissolved in dry acetonitrile. To the mixture was
added 460.1 mg (1.479 equiv, 1.416 mmol) of Cs2CO3 at room temperature and was
stirred for 45 min. After 45 min., 0.30 mL (5.0 equiv, 4.8 mmol) of CH3I was added to
the solution dropwise at room temperature, and the mixture was stirred for 1 h. The
solution was quenched with H2O and rotary evaporated on the high vacuum.

The

remaining oil was dissolved in DCM and washed with H2O (2  5 mL) and dried with
anhyd MgSO4. The drying agent was filtered off, and the solvent was rotary evaporated
off leaving a yellow oil. The desired product was purified with an elution of 2:1.5:0.1
mixture of hexanes to EtOAc to CHCl3 on silica gel chromatography to give 118.5 mg
(47.0% yield) 1H NMR:  1.22 (9H, s, C(CH3)3), 2.94 (3H, s, NCH3), 5.03 (1H, s,
CHNCH3), 7.517.76 (4H, m, ArH);

C NMR:  27.52 (C(CH3)3, 27.63 (NCH3), 30.74

13

(C(CH3)3), 54.35 (CHNCH3), 71.74 (CC), 96.48 (CC), 121.03, 124.64, 129.61, 133.10,
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134.02, 135.69 (Ar); DARTHRMS: Calcd for C14H17NO2S m/z 263.09800; found [M +
H]+ m/z 264.10690 (calcd m/z 264.10582).
Synthesis of 3-(m-vinylphenyl)-1,2-benzisothiazole 1,1-dioxide (26-1)
In an oven dried 2-necked flask, addition funnel, and reflux column was added 100.8 mg
(1.000 equiv, 4.147 mmol) Mg0 turnings, and the apparatus was purged with nitrogen for
20 min. After 20 min. of purging, dry THF was added to the flask, and the mixture was
purged for 20 min and stirred vigorously. After bringing the mixture to reflux, a solution
of 0.7595 g (4.149 mmol) of 3-bromostyrene (Matrix Scientific) in dry THF was added
dropwise to the solution. The reaction was stirred at reflux until the solution turned a
yellow-brown color, and the magnesium turnings no longer remained. In a oven-dried
round-bottom flask was dissolved 722.3 mg (0.9503 equiv, 3.943mmol) of saccharin in
dry THF, and the solution was purged with nitrogen and brought to 0 C. At 0 C, 3.95
mL of a 1.0 M solution of phenyl magnesium bromide (SigmaAldrich) (0.952 equiv,
3.95 mmol) was added dropwise at 0 C to the saccharin solution to deprotonate the
saccharin. After stirring for some time at 0 C, the (3-vinylphenyl)magnesium bromide
solution was added dropwise to the solution of deprotonated saccharin at 0 C with
warming to room temperature. The solution was allowed to stir overnight under nitrogen.
The reaction was quenched with ice water and then brought to pH 1 with 1 N HCl. The
organic compound was extracted with Et2O, and washed with a 10% NaHCO3 solution
to remove unreacted saccharin. The organic layer was dried with anhyd MgSO4, filtered,
and rotary evaporated to produce a yellow solid. The desired product was purified on
silica gel chromatography with an elution of 2:1 mixture of petroleum ether to EtOAc to
give 660.4 mg (62.19% yield). 1H NMR:  5.42 (1H, d, J = 10 Hz CH=CH2), 5.89 (1H, d,
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J = 20 Hz, CH=CH2), 6.81 (1H, quartet, J = 10 Hz, J = 20 Hz, CH=CH2), 7.58 (1H, t, J =
10 Hz, ArH), 7.72-7.85 (4H, m, ArH), 7.89-7.91 (1H, m, ArH), 7.99 (1H, t, J = 5.0 Hz,
ArH), 8.02-8.04 (1H, m, ArH);

C NMR:  116.23 (CH=CH2), 123.10 (Ar), 126.51 (Ar),
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127.18 (Ar), 128.54 (Ar), 129.36 (Ar), 130.54 (Ar), 130.75 (Ar), 130.89 (Ar), 133.42 (Ar),
133.66 (Ar), 135.43 (CH=CH2), 138.85 (Ar), 141.10 (Ar), 170.99 (C=N). DARTHRMS:
Calcd for C15H12NO2S m/z 269.31834; [M +H]+ m/z 270.06044 (calcd m/z 270.05887).
Synthesis of (S)-3-(m-vinylphenyl)-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide (262)
In an oven-dried flask, 660.4 mg (2.452 mmol) of 3-(m-vinylphenyl)-1,2-benzisothiazole
1,1-dioxide (26-1) was added to dry DCM. With a ratio of 200:1 imine to catalyst, 8.9 mg
(0.014 mmol) of pre-formed Cp*RhCl[(1R,2R)-p-TsNCH(C6H5)CH(C6H5)NH2] was
added, and the mixture was stirred at room temperature under nitrogen. At this time, 0.4
mL of an azeotropic mixture of 5:2 formic acidtriethylamine was added, and the
reaction was stirred for 30 min. After evidence that the substrate had disappeared by
TLC, the reaction was worked-up with 1 M NaHCO3 and extracted with DCM. The
combined organic phase was washed with brine, dried over MgSO4, and concentrated
to give a crude product. The desired product was purified on silica gel chromatography
with an elution of 2:1 mixture of hexanes to EtOAc to give 620.0 mg (93.16%) []
+119° (c=0.1, CHCl3); 1H NMR:  5.05 (1H, s, NH), 5.28 (1H, d, J = 10 Hz, CH=CH2),
5.71 (1H, d, J = 5 Hz, CHNH), 5.76 (1H, d, J = 20 Hz, CH=CH2), 6.68 (1H, quartet, J =
10 Hz, J = 20 Hz, CH=CH2), 7.13-7.83 (8H, m, ArH); 13C NMR:  61.28 (CHNH), 115.12
(CH=CH2), 121.15 (CH=CH2), 125.33, 125.40, 126.76, 126.87, 129.47, 129.51, 133.33,
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134.78, 136.01, 138.64, 139.00, 139.65 (Ar); Calcd for C 15H13NO2S m/z 271.06670;
found [M + H]+ m/z 272.07352 (calcd m/z 272.07452).
Synthesis of (S)-3-(m-vinylphenyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1dioxide (26-3)
To a solution of 620.0 mg (2.285 mmol) (S)-3-(m-vinylphenyl)-2,3-dihydro-1,2benzisothiazole 1,1-dioxide (26-2) in dry acetonitrile was added 1.4800 g (1.9929 equiv,
4.5538 mmol) of Cs2CO3. The mixture stirred for 1 h, at which time 0.29 mL (2.1 equiv,
4.7 mmol) of CH3I were added, and the mixture stirred until completion of the reaction
as shown by TLC. The reaction was quenched with water, and the mixture was rotary
evaporated under high vacuum. The product was taken up in DCM, and washed with
water (3  15 mL) followed by a brine wash. The organic phase was dried with anhyd
MgSO4, and rotary evaporated. The desired product was purified on silica gel
chromatography with an elution of 2:1 hexanes to EtOAc to give 254.8 mg (39.08%
yield). []

+138° (c=0.1, CHCl3); 1H NMR:  2.78 (3H, s, NCH3), 5.18 (1H, s, CHN), 5.29

(1H, d, J = 10 Hz, CH=CH2), 5.77 (1H, d, J = 20 Hz, CH=CH2), 6.70 (1H, quartet, J = 10
Hz, J = 20 Hz, CH=CH2), 7.03-7.86 (8H, m, ArH);

C NMR:  27.51 (NCH3), 66.94
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(CHN), 115.01 (CH=CH2), 121.12 (CH=CH2), 124.98, 125.91, 126.84, 127.50, 129.33,
129.40, 132.97, 134.06, 136.07, 136.99, 138.24, 138.58 (Ar); DARTHRMS: Calcd for
C16H15NO2S m/z 285.36080; found [M + H]+ m/z 286.09156 (calcd m/z 286.09017).
Synthesis

of

(S)-3-(m-cyclopropylphenyl)-2,3-dihydro-2-methyl-1,2-

benzisothiazole 1,1-dioxide (26-4)
In an oven-dried flask was dissolved 180.6 mg (2.002 equiv, 0.9812 mmol) of
pentafluorophenol in dry dichlorohmethane under nitrogen. The solution is brought to
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40 C, and 0.98 mL of 1 M Et2Zn (2.0 equiv, 0.98 mmol) is added to the solution to stir
for 15 min. After 15 min. has passed, 0.10 mL (2.5 equiv, 1,2 mmol) of CH2I2 is added to
the solution to continue stirring for 15 min. at 40 C. After 15 min has passed, a
solution of 140.0 mg of sultam 26-3 (1.000 equiv, 0.4901 mmol) in dry dichloromethane
is added, and the cold bath is removed to allow the reaction to warm to room
temperature. The reaction was stirred for 18 h. The reaction was washed with 10% aq
HCl (2  25 mL), satd aq NaHCO3 (2  25 mL), satd aq Na2SO3 (25 mL), and satd aq
NaCl (25 mL). The organic layer was dried over MgSO4, filtered, and rotary evaporated.
The product was purified on silica gel chromatography with an elution of 2:1 hexanes to
EtOAc to give 78.1 mg (53.2% yield). []

+117° (c=0.1, CHCl3); 1H NMR  0.68 (2H, m,

CHCH2CH2), 0.97 (2H, m, CHCH2CH2), 1.88 (1H, m, CHCH2CH2), 2.76 (3H, s, NCH3),
5.13 (1H, s, CHN), 7.01-7.84 (8H, m, ArH);

C NMR  9.57 (CHCH2CH2), 9.62
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(CHCH2CH2), 15.36 (CH2CHCH2), 27.42 (NCH3), 67.04 (CHNCH3), 121.06, 124.99,
125.20, 125.67, 125.85, 129.07, 129.25, 132.92, 134.01, 136.09, 138.44, 145.31 (Ar);
DARTHRMS: Calcd for C17H17NO2S m/z 299.38738; found [M + H]+ m/z 300.10610
(calcd m/z 300.10582).
Synthesis

of

3,3-bis(cyclopropylethynyl)-2,3-dihydro-1,2-benzisothiazole

1,1-

dioxide (12-1)
In a dry flask was dissolved 301.0 mg (4.554 mmol) of ethynylcyclopropane in 10 mL of
dry THF. The solution was stirred and cooled to –78 °C under a nitrogen atmosphere.
At this time, 1.90 mL (4.56 mmol, 1.00 equiv) of 2.4 M n-BuLi solution in hexanes were
added via syringe. The reaction was left to stir for 4 h at 78 C. A second solution of
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dry THF and 457.7 mg (0.4985 equiv, 2.270 mmol) of 3-chloro-1,2-benzisothiazole 1,1dioxide (9-1) was added dropwise to the solution of lithiated ethynylcyclopropane at –78
°C. The mixture was allowed to warm to 10 °C over an hour, and the reaction was
worked up with satd aq NH4Cl and allowed to warm up to room temperature. The solid
was filtered off, and the two layers were separated. An Et 2O extraction was performed
on the aqueous layer, and combined with the organic layer. The organic layer was
dried with anhyd MgSO4, which was filtered off, and the solvent was rotary evaporated
off leaving a solid. The desired product was purified on silica gel chromatography by
eluting with a 3:1 mixture of Et2O to hexane to purify the product to give 472.3 mg
(69.53% yield).

H NMR:  0.62-0.78 (8H, m, CHCH2CH2), 1.17-1.26 (2H, m,

1

CH2CHCH2), 5.17 (1H, s, NH), 7.44-7.57 (1H, m, ArH), 7.64-7.70 (3H, m, ArH);

13

C

NMR:  -0.74 (CH2CHCH2), 8.35 (CHCH2CH2), 52.29 (CN), 72.11 (CC), 88.59 (CC),
120.95, 124.90, 134.04, 133.29, 133.99, 140.73 (Ar); DARTHRMS: Calcd for
C17H15NO2S m/z 297.37150; found [M + H]+ m/z 298.08973 (calcd m/z 298.09017).
Synthesis

of

3,3-bis(cyclobutylethynyl)-2,3-dihydro-1,2-benzisothiazole

1,1-

dioxide (12-2)
In a dry flask was dissolved 3.7623 g (0.032270 mol) of 6-chlorohexyne in dry THF. The
mixture was brought to 78 C and 29.8 mL (0.0685 mol, 2.12 equiv) of 2.3 M n-BuLi
was slowly injected for 20 min, whereupon the mixture was kept at 78 C for at least 20
min afterwards. This solution was warmed to room temperature overnight, quenched
with NH4Cl, extracted with Et2O, dried with anhyd MgSO4, and the Et2O was distilled of
to leave the product in THF. 4 Å Molecular sieves were added to the solution, and it was
cooled to 78 C. At this time, 14.0 mL (0.0323 mol, 1.00 equiv) of 2.3 M n-BuLi was
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added to the solution dropwise, and the mixture was stirred for 4 h at 78 C. A solution
of 3.2482 g (0.016110 mol, 0.50000 equiv) of 3-chloro-1,2-benzisothiazole 1,1-dioxide
(9-1) in dry THF was added dropwise to the solution of lithiated ethynylcyclobutane, and
the mixture was allowed to warm to 10 C over 1 h. The reaction mixture was worked up
with satd aq NH4Cl and allowed to warm up to room temperature. The solid was filtered
off, and the two layers were separated. An Et2O extraction was performed on the
aqueous layer, and combined with the organic layer. The organic layer was dried with
anhyd MgSO4, which was filtered off, and the solvent was rotary evaporated off leaving
a solid. The desired product was purified on silica gel chromatography with an elution
of a 2:1 petroleum ether and EtOAc to purify the desired product at 0.7764 g (14.81%
yield). 1H NMR:  1.79-1.93 (4H, m, CH2CH2CH2), 2.03-2.15 (4H, m, CHCH2CH2), 2.152.24 (4H, m, CHCH2CH2) 2.98-3.05 (2H, quintet, CH2CHCH2), 5.06 (1H, s, CNH), 7.537.57 (1H, m, ArH), 7.66-7.70 (2H, m, ArH), 7.71-7.73 (1H, d, ArH);

C NMR:  19.15

13

(CH2CH2CH2), 24.67 (CH2CHCH2), 29.30 (CHCH2CH2), 29.31 (CHCH2CH2), 52.41
(CNH), 78.18 (CC), 89.13 (CC), 120.95, 124.98, 130.08, 133.46, 134.00, 140.97 (Ar).
DARTHRMS: Calcd for C19H19NO2S m/z 325.11365; found [M + H]+ m/z 326.12147
(calcd m/z 326.12124).
Synthesis of 3,3-bis(tert-butylethynyl)-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide
(12-3)
In a dry flask was dissolved 473.2 mg (5.761 mmol) of 3,3-dimethylbutyne in 10 mL of
dry THF. The solution was stirred and cooled to –78 °C under a nitrogen atmosphere.
At 78 C, 2.51 mL (1.00 equiv, 5.77 mmol) 2.3 M n-BuLi solution in hexanes were
added via syringe. The reaction was left to stir for 4 h while at 78 C. A second
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solution of dry THF and 580.8 mg (0.5000 equiv, 2.881 mmol of 3-chloro-1,2benzisothiazole 1,1-dioxide (9-1) was added dropwise to the solution of lithiated 3,3dimethylbutyne at –78 °C. The reaction mixture was allowed to warm to 10 °C over 1 h,
and the reaction was worked up with satd aq NH4Cl and allowed to warm up to room
temperature. The solid was filtered off, and the two layers were separated. An Et 2O
extraction was performed on the aqueous layer, and combined with the organic layer.
The organic layer was dried with anhyd MgSO4, which was filtered off, and the solvent
was rotary evaporated off leaving a solid. The desired product was purified on silica gel
chromatography by eluting with a 2:1 mixture of petroleum ether to EtOAc to purify the
product to give 837.1 mg 88.21% yield. 1H NMR:  1.18 (18H, s, C(CH3)3), 5.00 (1H, s,
NH), 7.53-7-72 (4H, m, ArH);

C NMR:  27.37 (C(CH3)3, 30.36 (C(CH3)3), 52.21

13

(CNH), 76.49 (CC), 93.43 (CC), 120.85, 124.76, 129.93, 133.47, 133.90, 141.41 (Ar);
DARTHRMS: Calcd for C19H23NO2S m/z 329.14495; found [M + H]+ m/z 330.15426
(calcd m/z 330.15277).
Synthesis of 3,3-bis(cyclopropylethynyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole
1,1-dioxide (25-4)
In a dry flask was dissolved 856.3 mg (2.880 mmol) of sultam 12-1 in dry CH3CN. Once
dissolved, the mixture was brought to 0 C, whereupon 2.7962 g (2.987 equiv, 8.604
mmol) of Cs2CO3 was added to the solution, followed by dropwise addition of 0.90 mL
(5.0 equiv, 14 mmol) of CH3I. The reaction was stirred at 0 C for 45 min, and the ice
bath was removed to warm the mixture to room temperature for 3 h. The mixture was
quenched with NH4Cl and extracted with EtOAc. The organic layer was washed with
H2O (2  15 mL) and a wash of brine. The organic layer was dried with anhyd MgSO4
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and filtered. The organic solvent was rotary evaporated, and the product was purified
on silica gel chromatography with an elution of 2:1 petroleum ether to EtOAc to give
845.7 mg (94.30 % yield). 1H NMR:  0.61-0.69 (4H, m, CH2CHCH2), 0.72-0.78 (4H, m,
CH2CHCH2), 1.20-1.26 (2H, m, CH2CHCH2), 2.93, (3H, s, NCH3), 7.52, (1H, t, ArH),
C NMR:  -0.59 (CH2CHCH2), 8.48 (CH2CHCH2), 8.52

13

7.62-7.71 (3H, m, ArH);

(CH2CHCH2), 25.02 (NCH3) 56.32 (CNCH3), 70.20 (CC), 89.70 (CC), 120.94, 124.66,
129.93, 132.70, 133.53, 138.66 (Ar); DARTHRMS: Calcd for C18H17NO2S m/z
311.39808; found [M + H]+ m/z 312.10698 (calcd m/z 312.10582).
Synthesis of 3,3-bis(cyclobutylethynyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole
1,1-dioxide (25-5)
In a dry flask was dissolved 89.4 mg (0.275 mmol) of sultam 12-2 in dry CH3CN, and the
solution was brought to 0 C. At 0 C, 134.4 mg of Cs2CO3 (1.503 equiv, 0.4135mmol)
was added, followed by the dropwise addition of 0.10 mL (5.8 equiv, 1.6 mmol) of CH3I.
After 45 min of stirring at 0 C, the ice bath was removed, and the mixture was stirred
for 3 h at room temperature. The reaction was quenched with satd aq NH4Cl and
washed with EtOAc. The organic layer was washed with H2O (2  15 mL) and a brine
solution. The organic layer was dried with anhyd MgSO4 and filtered. The organic
solvent was rotary evaporated, and the product was purified on silica gel
chromatography with an elution of 2:1 hexanes to EtOAc to give the desired product at
70.4 mg (75.4% yield).

H NMR:  1.84-1.97 (4H, m, CH2CH2CH2), 2.07-2.16 (4H, m,

1

CHCH2CH2), 2.22-2.28 (4H, m, CHCH2CH2), 3.01 (3H, m, NCH3), 3.04 (2H, quintet, J =
9.0 Hz CH2CHCH2), 7.57 (1H, t, J = 7.5 Hz, ArH), 7.68 (1H, t, J = 7.5 Hz, ArH), 7.74
(1H, d, J = 10.0 Hz, ArH), 7.78 (1H, d, J = 10.0 Hz, ArH);
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C NMR:  19.18

13

(CH2CH2CH2), 24.74 (CH2CHCH2), 25.08 (CNCH3), 29.52 (CHCH2CH2), 56.47
(CNCH3), 75.98 (CC), 90.07 (CC), 121.06, 124.69, 129.85, 132.82, 133.46, 138.93 (Ar)
DARTHRMS: Calcd for C20H21NO2S m/z 339.12930; found [M + H]+ m/z 340.13720
(calcd m/z 340.13712).
Synthesis

of 3,3-bis(tert-butylethynyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole

1,1-dioxide (25-6)
In a dry flask was dissolved 837.1 mg (2.541 mmol) of sultam 12-3 in dry CH3CN. Once
dissolved, the solution was brought to 0 C, and 2.4916 g (3.0171, 7.6665 mmol) of
Cs2CO3 was added to the solution, followed by the dropwise addition of 0.80 mL (5.1
equiv, 13 mmol) of CH3I to the solution. The mixture was stirred for 45 min at 0 C, and
the ice bath was removed allowing the reaction to warm to room temperature for 3 h.
The reaction was quenched with satd aq NH4Cl, and the mixture was extracted with
EtOAc. The organic layer was washed with H2O (2  15 mL) and then a brine solution.
The organic layer was separated, dried with anhyd MgSO4, and filtered. The organic
solvent was rotary evaporated, and the compound was purified on silica gel
chromatography with an elution of 4:1 petroleum ether to EtOAc to give 749.0 mg
(85.82% yield).

H NMR:  0.61-0.71 (4H, m, CH2CHCH2), 0.72-0.79 (4H, m,

1

CH2CHCH2), 1.20-1.26 (2H, m, CH2CHCH2), 2.93 (3H, s, NCH3), 7.52 (1H, t, ArH), 7.627.71 (3H, m, ArH);

C NMR:  -0.59 (CH2CHCH2), 8.62 (CH2CHCH2), 25.00 (NCH3),

13

56.27 (CNCH3), 70.30 (CC), 89.74 (CC), 121.05, 124.53, 129.78, 132.41, 133.49,
138.75 (Ar); DARTHRMS: Calcd for C20H25NO2S m/z 343.48300; found [M + H]+ m/z
344.17032 (calcd m/z 344.16842).
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5:2 Formic acid: triethylamine azeotrope
A distillation apparatus was set up with a Vigreux column (15 cm) between the roundbottom flask and the distilling head, and a water condenser leading to a bent vacuum
adapter with a bent dropper attached to a distillation cow. An approximate ratio of 5:2
molar mixture of 98% formic acid and triethylamine were poured into the round-bottom
flask with triethylamine being poured first. The round-bottom flask was placed in a sand
bath that was brought to approximately 200 °C. The first fraction to come off was
triethylamine at 88 °C, followed by formic acid at 100.8 °C. The thermometer for some
time showed a distillate at approximately 110 °C. Once this distillate was collected, the
air condenser was removed, placing the still head directly on the round-bottom flask. As
the temperature rose up to 190 °C, these fractions were collected separately. Once 190
°C was reached, the distillation cow was turned so that a clean collector would collect
the azeotrope. The azeotrope was collected until either a change in temperature or
before all liquid was distilled to prevent distilling to dry.

An NMR spectrum was

performed on the azeotrope to confirm the 5:2 ratio. The formyl H in formic acid has a
shift at 8.25 ppm, and the triethylamine has the 3 CH2 groups with a shift at 3.0 ppm,
and the 3 CH3 groups with a shift at 1.2 ppm. The integrations on these peaks were
normalized so that the methyl groups integrated to 18.00, resulting in the CH 2 groups
integrated to 12.13, and the formyl group integrated to 4.46.
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1

H NMR (500 MHz, CDCl3) of 3-chloro-1,2-benzisothiazole 1,1-dioxide
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13

C NMR (500 MHz, CDCl3) of 3-chloro-1,2-benzisothiazole 1,1dioxide
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1

H NMR (500 MHz, CDCl3) of 3-cyclopropylethynyl-1,2benzisothiazole 1,1-dioxide
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13

C NMR (500 MHz, CDCl3) of 3-cyclopropylethynyl-1,2benzisothiazole 1,1-dioxide
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1

H NMR (500 MHz, CDCl3) of 3-(cyclobutylethynyl)-1,2benzisothiazole 1,1-dioxide
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13

C NMR (500 MHz, CDCl3) of 3-(cyclobutylethynyl)-1,2benzisothiazole 1,1-dioxide
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1

H NMR (500 MHz, CDCl3) of 3-(tert-butylethynyl)-1,2benzisothiazole 1,1-dioxide
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13

C NMR (500 MHz, CDCl3) of 3-(tert-butylethynyl)-1,2benzisothiazole 1,1-dioxide
130

1

H NMR (500 MHz, CDCl3) of 3-(cyclopropylethynyl)-2,3dihydro-1,2-benzisothiazole 1,1-dioxide
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13

C NMR (500 MHz, CDCl3) of 3-(cyclopropylethynyl)-2,3dihydro-1,2-benzisothiazole 1,1-dioxide
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1

H NMR (500 MHz, CDCl3) of 3-(cyclobutylethynyl)-2,3dihydro-1,2-benzisothiazole 1,1-dioxide
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13

C NMR (500 MHz, CDCl3) of 3-(cyclobutylethynyl)-2,3-dihydro-1,2benzisothiazole 1,1-dioxide
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1

H NMR (500 MHz, CDCl3) of 3-(t-butylethynyl)-2,3-dihydro-1,2benzisothiazole 1,1-dioxide
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13

C NMR (500 MHz, CDCl3) of 3-(t-butylethynyl)-2,3dihydro-1,2-benzisothiazole 1,1-dioxide
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1

H NMR (500 MHz, CDCl3) of 3-(cyclopropylethynyl)2,3-dihydro-3-methyl-1,2-benzisothiazole 1,1-dioxide
137

13

C NMR (500 MHz, CDCl3) of 3-(cyclopropylethynyl)-2,3-dihydro-3methyl-1,2-benzisothiazole 1,1-dioxide
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1

H NMR (500 MHz, CDCl3) of 3-(cyclobutylethynyl)-2,3-dihydro-2,methyl1,2-benzisothiazole 1,1-dioxide
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13

C NMR (500 MHz, CDCl3) of 3-(cyclobutylethynyl)-2,3dihydro-3-methyl-1,2-benzisothiazole 1,1-dioxide
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13

C NMR (500 MHz, CDCl3) of 3-(t-butylethynyl)-2,3-dihydro2,methyl-1,2-benzisothiazole 1,1-dioxide
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13

C NMR(500 MHz, CDCl3) of 3-(t-butylethynyl)-2,3-dihydro2,methyl-1,2-benzisothiazole 1,1-dioxide
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1

H NMR (500 MHz, CDCl3) of 3-(3-vinylphenyl)-1,2benzisothiazole 1,1-dioxide
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13

C NMR (500 MHz, CDCl3) of 3-(3-vinylphenyl)-1,2benzisothiazole 1,1-dioxide
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1

H NMR (500 MHz, CDCl3) of (S)-3-(3-vinylphenyl)-2,3dihydro-1,2-benzisothiazole 1,1-dioxide
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C NMR (500 MHz, CDCl3) of (S)-3-(3-vinylphenyl)-2,3-dihydro1,2-benzisothiazole 1,1-dioxide
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H NMR (500 MHz, CDCl3) of (S)-2-methyl-3-(3-vinylphenyl)-2,3dihydro-1,2-benzisothiazole 1,1-dioxide
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C NMR (500 MHz, CDCl3) of (S)-2-methyl-3-(3-vinylphenyl)2,3-dihydro-1,2-benzisothiazole 1,1-dioxide
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1

H of (500 MHz, CDCl3) (S)-3-(3-cyclopropylphenyl)-2,3-dihydro-2methyl-1,2-benzisothiazole 1,1-dioxide
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13

C NMR (500 MHz, CDCl3) of (S)-3-(3cyclopropylphenyl)-2,3-dihydro-2-methyl-1,2benzisothiazole 1,1-dioxide
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1

H NMR (500 MHz, CDCl3) of 3,3-bis
(cyclopropylethynyl)-2,3-dihydro-1,2-benzoisothiazole
1,1-dioxide
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13

C NMR (500 MHz, CDCl3) of 3,3-bis (cyclopropylethynyl)-2,3dihydro-1,2-benzisothiazole 1,1-dioxide
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1

H NMR (500 MHz, CDCl3) of 3,3-bis (t-butylethynyl)-2,3-dihydro-1,2benzisothiazole 1,1-dioxide
153

13

C NMR (500 MHz, CDCl3) of 3,3-bis (t-butylethynyl)-2,3-dihydro-1,2benzisothiazole 1,1-dioxide
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1

H NMR (500 MHz, CDCl3) of 3,3-bis (cyclobutylethynyl)-2,3dihydro-1,2-benzoisothiazole 1,1-dioxide
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13

C NMR (500 MHz, CDCl3) of 3,3-bis (cyclobutylethynyl)-2,3dihydro-1,2-benzoisothiazole 1,1-dioxide
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1

H NMR (500 MHz, CDCl3) of 3,3-bis (cyclopropylethynyl)-2,3-dihydro2-methyl-1,2-benzoisothiazole 1,1-dioxide
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13

C NMR (500 MHz, CDCl3) of 3,3-bis (cyclopropylethynyl)-2,3dihydro-2-methyl-1,2-benzoisothiazole 1,1-dioxide
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1

H NMR (500 MHz, CDCl3) of 3,3-bis (t-butylethynyl)-2,3-dihydro-2-methyl1,2-benzoisothiazole 1,1-dioxide
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13

C NMR (500 MHz, CDCl3) of 3,3-bis (t-butylethynyl)-2,3-dihydro-2-methyl1,2-benzoisothiazole 1,1-dioxide
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1

H NMR (500 MHz, CDCl3) of 3,3-bis (cyclobutylethynyl)-2,3-dihydro-2methyl-1,2-benzoisothiazole 1,1-dioxide
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13

C NMR (500 MHz, CDCl3) of 3,3-bis (cyclobutylethynyl)-2,3dihydro-2-methyl-1,2-benzoisothiazole 1,1-dioxide
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